<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="pmc-domain-id">349</journal-id><journal-id journal-id-type="pmc-domain">plospath</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431654</article-id><article-id pub-id-type="pmcid-ver">PMC12431654.1</article-id><article-id pub-id-type="pmcaid">12431654</article-id><article-id pub-id-type="pmcaiid">12431654</article-id><article-id pub-id-type="pmid">40920828</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1013457</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-25-00752</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Animal Models of Disease</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Analysis of Variance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Analysis of Variance</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Transfection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Transfection</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Activation of PD-1/PD-L1 immune checkpoint by Zika virus</article-title><alt-title alt-title-type="running-head">Zika virus activates PD-L1 immune checkpoint</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chenxi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Xie</surname><given-names initials="Y">Yubin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="W">Weixin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ong</surname><given-names initials="CP">Chon Phin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="H">Hao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="S">Shuofeng</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="G">Gong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2778-3530</contrib-id><name name-style="western"><surname>Jin</surname><given-names initials="DY">Dong-Yan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ye</surname><given-names initials="ZW">Zi-Wei</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Microbiology and State Key Laboratory of Emerging Infectious Diseases, LKS Faculty of Medicine, Pokfulam, Hong KongChina</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Tsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Aliota</surname><given-names initials="MT">Matthew T</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Minnesota Twin Cities, UNITED STATES OF AMERICA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interest exists.</p></fn><corresp id="cor001">* E-mail: <email>zwye@hku.hk</email> (ZWY) and <email>dyjin@hku.hk</email> (DYJ)</corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>21</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496175</issue-id><elocation-id>e1013457</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 15:25:32.480"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Wang et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ppat.1013457.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="ppat.1013457.pdf"/><abstract><p>Zika virus (ZIKV) has emerged as a rising concern in global health in recent years. The role of PD-1/PD-L1 immune checkpoint in acute ZIKV infection remains to be understood. In this study we demonstrated the activation of PD-1/PD-L1 immune checkpoint by ZIKV. mRNA and protein expression of PD-L1 was boosted by ZIKV not only in SF268 and JEG3 cell lines but also in human dendritic cells. PD-1 expression was more abundant on CD8<sup>+</sup> T cells in ZIKV-infected mice. Elevated PD-L1 expression was also observed in the brain, testis and spleen of ZIKV-infected A129 mice. Blocking PD-L1 effectively inhibited ZIKV infection, reducing viral loads in all tissues. In addition, anti-PD-L1 antibody treatment further increased virus-specific CD8<sup>+</sup> T cells, KLRG<sup>+</sup> CD8<sup>+</sup> T cells, and effector memory CD8<sup>+</sup> T cells. PD-L1 blockade also induced interferon &#947;, granzyme B, and interleukin 2 expression in antigen-specific CD8<sup>+</sup> T cells, consistent with activation of these cells. Mechanistically, the induction of PD-L1 expression might be ascribed to viral NS4B protein and its interaction with GRP78. Our findings suggest that targeting the PD-1/PD-L1 pathway could have antiviral effect against ZIKV.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Immune checkpoint blockade has become another pillar in cancer treatment, but whether the same strategy might be used in antiviral therapy remains to be clarified. In this study we used ZIKV infection as an example to understand immune checkpoint activation during acute infection. The activation of the PD-1/PD-L1 immune checkpoint by ZIKV was demonstrated by several lines of evidence. Blocking this checkpoint using anti-PD-L1 antibodies effectively inhibited ZIKV infection in mice, reducing viral burdens in all tissues, consistent with enhanced virus-specific T cell response. It was further found that the ability to induce PD-L1 expression would be ascribed to one viral protein named NS4B and its interaction with another cellular protein GRP78. Our work revealed a new antiviral strategy against ZIKV by blocking the PD-1/PD-L1 immune checkpoint.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Natural Science Foundation of China</institution></funding-source><award-id>N-HKU 723/19</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2778-3530</contrib-id><name name-style="western"><surname>Jin</surname><given-names>Dong-Yan</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Natural Science Foundation of China</institution></funding-source><award-id>32300135</award-id><principal-award-recipient><name name-style="western"><surname>Ye</surname><given-names>Zi-Wei</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Health and Medical Research Fund</institution></funding-source><award-id>24230822</award-id><principal-award-recipient><name name-style="western"><surname>Ye</surname><given-names>Zi-Wei</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Health and Medical Research Fund</institution></funding-source><award-id>CID-HKU1-9</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2778-3530</contrib-id><name name-style="western"><surname>Jin</surname><given-names>Dong-Yan</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>InnoHK</institution></funding-source><award-id>CVVT</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2778-3530</contrib-id><name name-style="western"><surname>Jin</surname><given-names>Dong-Yan</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by RGC-NSFC JRS grant N-HKU 723/19 (awarded to D.-Y.J.), NSFC-YS grant 32300135 (awarded to Z.-W.Y.), Health and Medical Research Fund (HMRF) grant 24230822 (awarded to Z.-W.Y.), HMRF commissioned grant CID-HKU1-9 (awarded to D.-Y.J.) and InnoHK (D.-Y.J. is a member in CVVT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="22"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The mass spectrometry data in this manuscript have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD062250 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD062250" ext-link-type="uri">https://www.ebi.ac.uk/pride/archive/projects/PXD062250)</ext-link>. All other relevant data are within the manuscript and its <xref rid="sec015" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2025-09-12</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The mass spectrometry data in this manuscript have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD062250 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD062250" ext-link-type="uri">https://www.ebi.ac.uk/pride/archive/projects/PXD062250)</ext-link>. All other relevant data are within the manuscript and its <xref rid="sec015" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Zika virus (ZIKV) has raised fresh concerns in global health in recent years. Since its discovery in Uganda in 1947, this mosquito-borne virus has spread to 89 countries worldwide. ZIKV is primarily transmitted to humans through the bite of an infected <italic toggle="yes">Aedes</italic> mosquito. It can also be sexually transmitted, leading to testicular damage and prolonged presence in semen and vaginal secretions [<xref rid="ppat.1013457.ref001" ref-type="bibr">1</xref>]. While most individuals infected with ZIKV experience mild symptoms such as fever, rash, conjunctivitis, and muscle pain, the virus poses a severe risk during pregnancy by crossing the placenta to cause birth defects like microcephaly and congenital malformations in fetuses and newborn infants [<xref rid="ppat.1013457.ref002" ref-type="bibr">2</xref>]. Additionally, ZIKV could also cause Guillain-Barr&#233; syndrome (GBS) and meningoencephalitis in infected adults [<xref rid="ppat.1013457.ref003" ref-type="bibr">3</xref>]. The lack of vaccines or antivirals poses an urgent need to advance our understanding of the biology and immunology of ZIKV infection.</p><p>Both innate and adaptive immune systems play pivotal roles in the host response against ZIKV infection [<xref rid="ppat.1013457.ref004" ref-type="bibr">4</xref>,<xref rid="ppat.1013457.ref005" ref-type="bibr">5</xref>]. The interferon (IFN) system serves as a critical host innate antiviral defense. Elevated levels of IFN-&#945;, IFN-&#946;, TLR3, RIG-I and other innate immune mediators have been reported in patients infected with ZIKV [<xref rid="ppat.1013457.ref006" ref-type="bibr">6</xref>]. The expression of type I IFN-stimulated genes such as IFITM1 and IFITM3 also inhibits ZIKV infection [<xref rid="ppat.1013457.ref007" ref-type="bibr">7</xref>]. To evade the host&#8217;s antiviral response and facilitate replication, ZIKV has developed various evasion strategies [<xref rid="ppat.1013457.ref008" ref-type="bibr">8</xref>]. Like other viruses in the <italic toggle="yes">Flaviviridae</italic> family, the ZIKV genome is translated into a single polyprotein, which is subsequently cleaved into three structural proteins &#8212; capsid, pre-membrane (prM) and envelope (E), as well as seven non-structural (NS) proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. ZIKV employs its multiple NS proteins to antagonize IFN response [<xref rid="ppat.1013457.ref009" ref-type="bibr">9</xref>]. Particularly, the NS1 protein stabilizes caspase 1 to cleave cGAS, which is activated by mitochondrial DNA during ZIKV infection [<xref rid="ppat.1013457.ref010" ref-type="bibr">10</xref>]. The NS2A protein facilitates degradation of STAT1 and STAT2 [<xref rid="ppat.1013457.ref011" ref-type="bibr">11</xref>]. The NS2B-NS3 protease of ZIKV is known to cleave STING [<xref rid="ppat.1013457.ref012" ref-type="bibr">12</xref>,<xref rid="ppat.1013457.ref013" ref-type="bibr">13</xref>], while the NS3 helicase targets RIG-I, MDA5 and MAVS [<xref rid="ppat.1013457.ref013" ref-type="bibr">13</xref>,<xref rid="ppat.1013457.ref014" ref-type="bibr">14</xref>]. The NS4A protein disrupts the interaction between RIG-I and MAVS [<xref rid="ppat.1013457.ref015" ref-type="bibr">15</xref>], whereas NS4B inhibits STAT1 phosphorylation [<xref rid="ppat.1013457.ref016" ref-type="bibr">16</xref>] and TBK1 activation [<xref rid="ppat.1013457.ref017" ref-type="bibr">17</xref>]. Notably, STAT2 is more specifically targeted by the NS5 protein [<xref rid="ppat.1013457.ref018" ref-type="bibr">18</xref>,<xref rid="ppat.1013457.ref019" ref-type="bibr">19</xref>]. Unlike dengue virus (DENV), the NS5 protein of ZIKV utilizes the ZSWIM8&#8211;CUL3 E3 ligase complex instead of UBR4 to degrade STAT2 [<xref rid="ppat.1013457.ref020" ref-type="bibr">20</xref>]. As such, ZIKV inhibits both STAT1 and STAT2 phosphorylation in primary human dendritic cells to antagonize type I IFN signaling [<xref rid="ppat.1013457.ref021" ref-type="bibr">21</xref>].</p><p>In addition to innate immune response, the importance of adaptive immunity in host defense against ZIKV has also been highlighted [<xref rid="ppat.1013457.ref005" ref-type="bibr">5</xref>,<xref rid="ppat.1013457.ref022" ref-type="bibr">22</xref>]. T cell activation in response to ZIKV infection is rather robust in both human and mouse models [<xref rid="ppat.1013457.ref008" ref-type="bibr">8</xref>]. Immunocompetent mice exposed to ZIKV exhibit a strong CD8<sup>+</sup> T cell response [<xref rid="ppat.1013457.ref023" ref-type="bibr">23</xref>,<xref rid="ppat.1013457.ref024" ref-type="bibr">24</xref>], which have both protective and cytotoxic effects [<xref rid="ppat.1013457.ref025" ref-type="bibr">25</xref>,<xref rid="ppat.1013457.ref026" ref-type="bibr">26</xref>]. Whereas the viral loads are reduced upon adoptive transfer of ZIKV-immune CD8<sup>+</sup> T cells, depletion of these cells results in higher viral burdens in tissues. In addition, ZIKV infection was more lethal in CD8<sup>-/-</sup> mice [<xref rid="ppat.1013457.ref008" ref-type="bibr">8</xref>]. In mice treated with anti-IFNAR antibodies without T cell depletion, body weight loss was not observed despite increased viral replication, suggesting that T cells play a crucial role in limiting ZIKV infection specifically when type I IFN response is compromised [<xref rid="ppat.1013457.ref027" ref-type="bibr">27</xref>]. In another model using IFNAR KO mice, depletion of CD8<sup>+</sup> T cells led to higher viral loads in the brain but resulted in improved survival rate and reduced paralysis [<xref rid="ppat.1013457.ref028" ref-type="bibr">28</xref>]. Interestingly, an epidemic Brazilian isolate of ZIKV from the outbreak potently suppressed CD8<sup>+</sup> T cell immunity in mice by perturbing antigen presentation [<xref rid="ppat.1013457.ref029" ref-type="bibr">29</xref>]. However, additional mechanisms by which ZIKV counteracts adaptive immunity remains to be further elucidated.</p><p>Programmed cell death receptor 1 (PD-1), a crucial inhibitory receptor in the CD28 superfamily, is specifically expressed in activated T cells. Its ligand PD-L1 is broadly expressed in various cell types, including antigen-presenting cells, epithelial cells and endothelial cells. Interaction between PD-1 and PD-L1/2 impedes T cell receptor signaling, leading to the suppression of T cell expansion and function [<xref rid="ppat.1013457.ref030" ref-type="bibr">30</xref>]. As such, immune checkpoint therapy based on PD-1/PD-L1-blocking antibodies has emerged as a new pillar of cancer therapy [<xref rid="ppat.1013457.ref030" ref-type="bibr">30</xref>,<xref rid="ppat.1013457.ref031" ref-type="bibr">31</xref>]. Notably, the upregulation of PD-1/PD-L1 during acute virus infection also results in the suppression of T cell response [<xref rid="ppat.1013457.ref032" ref-type="bibr">32</xref>]. For example, in mice infected with acute lymphocytic choriomeningitis virus (LCMV), PD-1 expression rapidly increases upon activation of naive virus-specific CD8<sup>+</sup> T cells within 24 hours post-infection. Blocking the PD-1 pathway using anti-PD-L1 or anti-PD-1 antibodies during the early phase of acute LCMV infection results in accelerated clearance of the virus [<xref rid="ppat.1013457.ref033" ref-type="bibr">33</xref>]. Likewise, metapneumovirus and influenza A also upregulate PD-1 and PD-L1 to impair CD8<sup>+</sup> T cells response [<xref rid="ppat.1013457.ref034" ref-type="bibr">34</xref>]. In addition, in infection with high-pathogenicity influenza virus, PD-1 expression on virus-specific CD8<sup>+</sup> T cells elevates, and <italic toggle="yes">in vivo</italic> blockade of PD-L1 leads to decreased viral replication and increased CD8<sup>+</sup> T cell function [<xref rid="ppat.1013457.ref035" ref-type="bibr">35</xref>]. Whereas the lack of PD-1 restores CD8<sup>+</sup> T cell function in mice [<xref rid="ppat.1013457.ref034" ref-type="bibr">34</xref>], genetic knockout of PD-L1 in mice does not restore CD8<sup>+</sup> T cell function and delays viral clearance [<xref rid="ppat.1013457.ref036" ref-type="bibr">36</xref>]. Although ZIKV has been shown to sensitize glioblastoma cells to anti-PD-L1 immunotherapy [<xref rid="ppat.1013457.ref037" ref-type="bibr">37</xref>], further investigations are required to clarify exactly how ZIKV affects the PD-1/PD-L1 immune checkpoint.</p><p>We report here that ZIKV infection leads to the upregulation of PD-L1 both in cultured cells and <italic toggle="yes">in vivo</italic>. Remarkably, blocking PD-L1 effectively suppressed ZIKV infection in A129 mice that are deficient of type I IFN signaling. Treatment with anti-PD-L1 antibodies enhanced the response of virus-specific CD8<sup>+</sup> T cells. The NS4B protein and its interaction partner GRP78 were identified in the functional screens for proteins that induce PD-L1 expression. Targeting the PD-1/PD-L1 pathway holds the promise to be another strategy in antiviral development against ZIKV.</p></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>ZIKV infection upregulates PD-L1 expression in cultured human cells</title><p>To shed light on the impact of ZIKV on host cells, we performed a comparative analysis of differentially expressed genes (DEGs) in ZIKV-infected JEG3 human choriocarcinoma cells (JEG-3), astrocytes (U-251 MG), and human renal proximal tubular epithelial cells (HK-2) using publicly available RNA-seq data [<xref rid="ppat.1013457.ref038" ref-type="bibr">38</xref>]. A total of 92 DEGs were overlapped in all three cell lines (<xref rid="ppat.1013457.s001" ref-type="supplementary-material">S1A Fig</xref>). Gene Ontology Biological Processes (GOBP) analysis revealed that most of these genes are associated with innate and adaptive immune responses as well as metabolic processes (<xref rid="ppat.1013457.s001" ref-type="supplementary-material">S1B Fig</xref>). Among the genes related to adaptive immune response, PD-L1 was consistently upregulated in all three cell lines (<xref rid="ppat.1013457.s001" ref-type="supplementary-material">S1C Fig</xref>). However, the functional relevance of PD-L1 upregulation in ZIKV infection has not been determined.</p><p>We verified the upregulation of PD-L1 during ZIKV infection. Human glioblastoma cell line SF268 was infected with ZIKV strain PRVABC59 at a multiplicity of infection (MOI) of 1 for 72 hours. The mRNA levels of PD-L1 increased as the viral infection progressed, peaking at 48 hours post-infection (hpi) (<xref rid="ppat.1013457.g001" ref-type="fig">Fig 1A</xref>). Consistent with this, Western blot analysis indicated elevated PD-L1 protein levels at 48 and 72 hpi (<xref rid="ppat.1013457.g001" ref-type="fig">Fig 1A</xref>). The same trend of PD-L1 upregulation at both mRNA and protein levels was also observed in ZIKV-infected JEG3 cells at 48 and 72 hpi (<xref rid="ppat.1013457.g001" ref-type="fig">Fig 1B</xref>). Flow cytometric analysis of infected SF268 and JEG3 cells showed a marked increase in PD-L1-positive cells and enhanced PD-L1 staining as indicated by the mean fluorescence intensity (MFI). (Figs 1C-1E and <xref rid="ppat.1013457.s002" ref-type="supplementary-material">S2</xref>A-<xref rid="ppat.1013457.s002" ref-type="supplementary-material">S2</xref>C). Notably, the same pattern of PD-L1 upregulation was also observed with ZIKV Uganda strain in both SF268 and JEG3 cells (<xref rid="ppat.1013457.s003" ref-type="supplementary-material">S3 Fig</xref>).</p><fig position="float" id="ppat.1013457.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g001</object-id><label>Fig 1</label><caption><title>ZIKV infection upregulates PD-L1 expression in cultured cells.</title><p>SF268 cells (<bold>A</bold>) and JEG3 cells (<bold>B</bold>) were infected with ZIKV strain PRVABC59 at a MOI of 1. Cell lysates were collected at 24, 48 and 72 hpi. The mRNA levels of PD-L1 were assessed using RT-qPCR. GAPDH was used as a housekeeping control. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed by two-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Protein levels of PD-L1 and envelope (E) protein were assessed by Western blotting with GAPDH as a loading control. Flow cytometric analysis of PD&#8208;L1 in SF268 cells upon ZIKV infection at 48 hpi. SF268 cells were analyzed for the expression of PD-L1 (gated on live cells) <bold>(C)</bold>, quantification of the frequency of PD-L1 positive cells <bold>(D)</bold>, quantification of the mean fluorescence intensity (MFI) of PD-L1 <bold>(E)</bold>. The PD-L1 expression in ZIKV-infected human dendritic cells (DCs) from donor A (<bold>F</bold>) and donor B <bold>(G)</bold>. DCs were infected with ZIKV at an MOI of 1. The mRNA levels of PD-L1 were assessed using RT-qPCR. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were carried out by two-way ANOVA (**<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g001.jpg"/></fig><p>Dendritic cells (DCs) are the major PD-L1-expressing cells [<xref rid="ppat.1013457.ref031" ref-type="bibr">31</xref>]. They are susceptible to ZIKV infection [<xref rid="ppat.1013457.ref021" ref-type="bibr">21</xref>]. As professional antigen presenting cells, they play a pivotal role in the activation of T cell response against ZIKV [<xref rid="ppat.1013457.ref039" ref-type="bibr">39</xref>]. We found that ZIKV infection induced PD-L1 expression in human DCs from different donors (<xref rid="ppat.1013457.g001" ref-type="fig">Fig 1F</xref> and <xref rid="ppat.1013457.g001" ref-type="fig">1G</xref>). These results indicate the induction of PD-L1 in a relevant and important type of human cells by ZIKV. Collectively, our findings demonstrate that ZIKV infection leads to the upregulation of PD-L1 expression.</p></sec><sec id="sec004"><title>ZIKV induces PD-L1 expression and T cell response <italic toggle="yes">in vivo</italic></title><p>We went on to determine the functional outcome of PD-L1 upregulation in ZIKV-infected cells. ZIKV infection triggers robust CD8<sup>+</sup> T cell response in C57BL/6 (B6) wild-type (WT) mice [<xref rid="ppat.1013457.ref023" ref-type="bibr">23</xref>,<xref rid="ppat.1013457.ref024" ref-type="bibr">24</xref>]. To confirm the activation of T cell response during ZIKV infection <italic toggle="yes">in vivo</italic>, B6 mice were intraperitoneally (i.p.) exposed to 2&#8201;&#215;&#8201;10<sup>6</sup> plaque-forming units (PFU) of the virus, and spleens were collected on 7 days post-infection (dpi) for analysis of T cell response (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2A</xref>). An increase in PD-1 expression on CD8<sup>+</sup> T cells was seen (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2B</xref>). A ZIKV-specific tetramer was used to evaluate and quantify antigen-specific T cells. The number of ZIKV-specific CD8<sup>+</sup> T cells in the spleens elevated (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2C</xref>). In addition, KLRG1<sup>+</sup> CD8<sup>+</sup> effector T cells and effector memory T cells (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2C</xref>) as well as CD8<sup>+</sup> T cells expressing granzyme B, interleukin 2 (IL-2) and IFN-&#947; (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2D</xref>) were more frequently detected in B6 mice following ZIKV infection, indicating the activation of CD8<sup>+</sup> T cell response <italic toggle="yes">in vivo</italic>.</p><fig position="float" id="ppat.1013457.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g002</object-id><label>Fig 2</label><caption><title>ZIKV infection induces T cell response and upregulates PD-L1 expression <italic toggle="yes">in vivo.</italic></title><p><bold>(A)</bold> Viral challenge scheme for the C57BL/6 model. C57BL/B6 mice were intraperitoneally (i.p.) exposed to 2&#8201;&#215;&#8201;10<sup>6</sup> PFU of the virus or PBS (n&#8201;=&#8201;5/group) at a final volume of 100 &#956;L. Spleens collected on 7 days post-infection (dpi) were subjected to flow cytometric analysis. The figure was created using BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>). <bold>(B)</bold> Flow cytometric analysis of CD8<sup>+</sup> activation upon ZIKV infection. Representative plots (left) and proportion of PD-1<sup>+</sup> cells (right) are shown. <bold>(C)</bold> Quantification of the frequency (Freq) of tetramer<sup>+</sup>, KLRG1<sup>+</sup>, and effector memory (EM) CD8<sup>+</sup> T cells. <bold>(D)</bold> Quantification of the frequency of granzyme B, IFN-&#947; and IL-2. Statistical analyses were performed by Student&#8217;s t-test (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). <bold>(E)</bold> Viral challenge scheme for the A129 mice model. A129 mice were i.p. exposed to 3&#8201;&#215;&#8201;10<sup>3</sup> PFU of the virus or PBS (n&#8201;=&#8201;4/group) at a final volume of 100 &#956;L. The figure was created using Biorender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>). <bold>(F)</bold> Brain, testis and spleen were collected on 8 dpi. Relative PD-L1 mRNA levels were detected using RT-qPCR analysis. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed by two-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g002.jpg"/></fig><p>However, since B6 mice infected with ZIKV were asymptomatic except for a mild gain in body weight, further assessment of the pathogenicity of ZIKV infection in this model was not possible. The IFN-&#945;/&#946; receptor-deficient A129 mice have been utilized as a lethal model for ZIKV infection [<xref rid="ppat.1013457.ref040" ref-type="bibr">40</xref>]. To confirm PD-L1 induction <italic toggle="yes">in vivo</italic>, A129 mice were i.p. infected with ZIKV, and the brain, testis and spleen were collected on 4 and 8 dpi (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2E</xref>). An upregulation of PD-L1 mRNA expression was noted in these tissues, particularly in the brain on 8 dpi (<xref rid="ppat.1013457.g002" ref-type="fig">Fig 2F</xref>), in support of the induction of PD-L1 expression by ZIKV <italic toggle="yes">in vivo</italic>.</p></sec><sec id="sec005"><title>PD&#8208;L1 blockade alleviates pathogenicity of ZIKV and elicits robust T cell response in mice</title><p>To interrogate the functional consequence of blocking PD-L1 in the context of ZIKV infection, male A129 mice were i.p. inoculated with ZIKV and subsequently treated with either an isotype control or a recombinant mouse monoclonal anti-PD-L1 antibody (Azeto) on 1, 3, 5 and 7 dpi (<xref rid="ppat.1013457.g003" ref-type="fig">Fig 3A</xref>). Notably, treatment with the anti-PD-L1 antibody dampened the viral loads in the brain and testis (<xref rid="ppat.1013457.g003" ref-type="fig">Fig 3B</xref> and <xref rid="ppat.1013457.g003" ref-type="fig">3C</xref>). Histopathological examination of the testis was performed using hematoxylin and eosin (H&amp;E) staining to compare inflammation and tissue damage between the IgG and anti-PD-L1 groups. At 8 dpi, minimal damage was observed in the testis of the anti-PD-L1-treated group compared to the IgG-treated group (<xref rid="ppat.1013457.g003" ref-type="fig">Fig 3D</xref>). To further evaluate the impact of PD-L1 blockade <italic toggle="yes">in vivo</italic>, male A129 mice were i. p. inoculated with 2&#8201;&#215;&#8201;10&#179; PFU of ZIKV and subsequently treated with either 150 &#956;g of either IgG control or anti-PD-L1 antibody on 2, 4, 6, and 8 dpi (<xref rid="ppat.1013457.s004" ref-type="supplementary-material">S4A Fig</xref>). The anti-IgG-treated group showed significantly higher clinical scores than the anti-PD-L1 group at 4&#8211;6 dpi, including reduced activity, pronounced hunching, and hind limb paralysis (<xref rid="ppat.1013457.s004" ref-type="supplementary-material">S4B Fig</xref>). Mice receiving the IgG control antibody showed a survival rate of 50%, whereas the anti-PD-L1-treated group had a higher survival rate of 62.5% (<xref rid="ppat.1013457.s004" ref-type="supplementary-material">S4C Fig</xref>). However, this difference was not statistically significant.</p><fig position="float" id="ppat.1013457.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g003</object-id><label>Fig 3</label><caption><title>PD-L1 blockade alleviates pathogenicity of ZIKV in A129 mice.</title><p><bold>(A)</bold> Antibody treatment and viral challenge scheme for the A129 model. Mice were inoculated intraperitoneally (i.p.) with 3&#8201;&#215;&#8201;10<sup>3</sup> PFU of ZIKV at a final volume of 100 &#956;L. Mice were i.p. treated with 200 &#956;g isotype control (&#945;IgG) or anti-PD-L1 antibody (&#945;PD-L1) at a final volume of 100 &#956;L on 1, 3, 5 and 7 dpi. Mock treatment was used as control. Mice were euthanized on day 8 post-virus challenge for sample harvest. The figure was created using BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>). <bold>(B)</bold> ZIKV viral titers in the brain and testis were determined using plaques assay (n&#8201;=&#8201;6/group). The dashed line represents the limit of detection (LOD). <bold>(C)</bold> ZIKV mRNA levels in the brain and testis were determined using RT-qPCR by detecting the E gene (n&#8201;=&#8201;6/group). Statistical analyses were performed by one-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). <bold>(D)</bold> Representative images of H&amp;E staining of testis sections. Scale bars: 50 &#956;m. Black arrows indicate tissue damage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g003.jpg"/></fig><p>To formally exclude the possibility that either the inhibition of PD-L1 or the anti-PD-L1 antibody used in the <italic toggle="yes">in vivo</italic> study has an unrecognized effect to result in the observed phenotypes, we asked whether PD-L1 blockade in cultured cells might affect ZIKV infection. Knockdown of PD-L1 expression in ZIKV-infected U251 cells with two independent siRNAs had no influence on ZIKV E protein expression (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5A Fig</xref>) or viral titer (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5B Fig</xref>). Consistent with this, E protein expression remained constant when PD-L1 expression was progressively increased (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5C Fig</xref>). In addition, ZIKV viral titers remained unchanged in cultured SF268 and U251 cells treated with the same anti-PD-L1 monoclonal antibody (Azeto) used in our <italic toggle="yes">in vivo</italic> studies (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5D Fig</xref>), suggesting that it did not exert any unexpected effect on ZIKV replication. Since this antibody directed against mouse PD-L1 might not recognize human PD-L1 optimally or cross the plasma membrane, we also tested whether ZIKV replication might be affected by small-molecule inhibitors of PD-L1 known as inhibitor 1 or BMS-1 [<xref rid="ppat.1013457.ref041" ref-type="bibr">41</xref>] and inhibitor 3 [<xref rid="ppat.1013457.ref042" ref-type="bibr">42</xref>]. Treatment of infected SF268 cells with either inhibitor did not suppress PD-L1 expression (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5E Fig</xref>) or viral load (<xref rid="ppat.1013457.s005" ref-type="supplementary-material">S5F Fig</xref>), indicating that PD-L1 blockade <italic toggle="yes">in vitro</italic> does not suppress ZIKV infection. In other words, its effects <italic toggle="yes">in vivo</italic> are plausibly attributed to T cell response.</p><p>Tetramer assay was next used to assess antigen-specific T cell response (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4A</xref>). We observed a more than 2-fold increase in E<sub>4-12</sub> tetramer-positive CD8<sup>+</sup> T cells in the splenocytes of the anti-PD-L1-treated group compared to the IgG-treated group on 8 dpi (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4B</xref>). The frequencies of KLRG1<sup>+</sup> CD8<sup>+</sup> effector T cells and effector memory T cells were further induced upon anti-PD-L1 treatment (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4C</xref>). The function of CD8<sup>+</sup> T cells in combating virus-infected cells usually involves production of cytokines such as IL-2 and IFN-&#947;. To further assess T-cell functionality, splenocytes were stimulated with E<sub>4-12</sub> (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4D</xref>) and NS3<sub>206&#8211;215</sub> (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4E</xref>) peptides derived from viral proteins. The frequencies of CD8<sup>+</sup> T cells expressing functional markers (CD107a and granzyme B) associated with cytotoxicity [<xref rid="ppat.1013457.ref043" ref-type="bibr">43</xref>], as well as those producing IFN-&#947; and IL-2, consistently elevated in the PD-L1 antibody-treated mice following peptide stimulation (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4D</xref> and <xref rid="ppat.1013457.g004" ref-type="fig">4E</xref>). These results indicate the potential of using anti-PD-L1 as an antiviral against ZIKV.</p><fig position="float" id="ppat.1013457.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g004</object-id><label>Fig 4</label><caption><title>PD-L1 blockade elicits robust T cell response in mice.</title><p><bold>(A)</bold> Antibody treatment, viral challenge and sampling scheme for the A129 model. The figure was created using BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>). <bold>(B)</bold> Representative flow tracings and the number of tetramer-specific CD8<sup>+</sup> T cells at 8 dpi. <bold>(C)</bold> Quantification of the frequency (Freq) of KLRG1<sup>+</sup> CD8<sup>+</sup> T cell and effector memory (EM) CD8<sup>+</sup> T cells. Splenocytes were stimulated with 2 &#956;g/ml E<sub>4-12</sub> (<bold>D</bold>) and NS3<sub>206-215</sub> (<bold>E</bold>) peptides for 5 hours in the presence of brefeldin <bold>A.</bold> The percentages of CD107a<sup>+</sup> and cytokine-producing CD8<sup>+</sup> T cells were assessed. The results are shown as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed with one-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g004.jpg"/></fig></sec><sec id="sec006"><title>NS4B induces PD-L1 expression by enhancing the activity of the PD-L1 promoter</title><p>As ZIKV infection leads to increased PD-L1 expression in cultured cells and <italic toggle="yes">in vivo</italic>, we attempted to identify the specific viral proteins responsible for this induction. Through transient expression of individual ZIKV NS genes in SF268 cells, we observed that the expression of either NS4A or NS4B resulted in elevated PD-L1 mRNA levels (<xref rid="ppat.1013457.g005" ref-type="fig">Fig 5A</xref>). Furthermore, both the mRNA and protein expression of PD-L1 showed a dose-dependent increase in response to NS4A and NS4B expression (<xref rid="ppat.1013457.g005" ref-type="fig">Fig 5B</xref> and <xref rid="ppat.1013457.g005" ref-type="fig">5C</xref>). To further investigate the mechanism by which NS4A and NS4B induce PD-L1 expression, we examined their impact on the PD-L1 promoter activity and found a more than 2-fold activation of the PD-L1 promoter activity by NS4B (<xref rid="ppat.1013457.g005" ref-type="fig">Fig 5D</xref>). A dose-dependent activation of the PD-L1 promoter activity was only seen with NS4B, not with NS4A (<xref rid="ppat.1013457.g005" ref-type="fig">Fig 5E</xref> and <xref rid="ppat.1013457.g005" ref-type="fig">5F</xref>), suggesting that NS4B is the major viral protein that induces PD-L1 expression by enhancing the activity of the PD-L1 promoter.</p><fig position="float" id="ppat.1013457.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g005</object-id><label>Fig 5</label><caption><title>NS4B induces PD-L1 expression by activating the PD-L1 promoter.</title><p><bold>(A)</bold> SF268 cells were transfected with 2 &#956;g of Flag-pCAGEN-NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 plasmid, respectively. At 24 hours post-transfection, the mRNA levels of PD-L1 were assessed using RT-qPCR. GAPDH was used as a housekeeping control. SF268 cells were transfected with increasing dose of Flag-tag NS4A (<bold>B</bold>) and NS4B (<bold>C</bold>) expression plasmids. Western blotting was performed with &#946;-tubulin as a loading control. The Western blotting results are representative of three independent experiments. <bold>(D)</bold> HEK293T cells were co-transfected with the NS plasmid and the PD-L1 promoter-driven reporter construct. At 24 hours post-transfection, luciferase activity was assessed using the Dual-Luciferase Reporter Assay System kit. HEK293T cells were co-transfected with increasing dose of NS4A (<bold>E</bold>) or NS4B (<bold>F</bold>) plasmid. The results are shown as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed with one-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g005.jpg"/></fig><p>PD-L1 is known to be upregulated by type I and type II IFN signaling [<xref rid="ppat.1013457.ref044" ref-type="bibr">44</xref>]. In this regard, we have previously shown selective activation of IFN-&#947; signaling by ZIKV and its NS5 protein [<xref rid="ppat.1013457.ref019" ref-type="bibr">19</xref>]. Although NS5 was not identified as an inducer of PD-L1 (<xref rid="ppat.1013457.g005" ref-type="fig">Fig 5A</xref> and <xref rid="ppat.1013457.g005" ref-type="fig">5D</xref>), it would still be of interest to determine whether ZIKV might induce PD-L1 expression through IFN signaling. To address this, JAK-STAT inhibitor AG490 [<xref rid="ppat.1013457.ref019" ref-type="bibr">19</xref>] was employed. Treatment of cells with AG490 reduced both basal and ZIKV-induced PD-L1 expression (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6A Fig</xref>). However, it remains to be further elucidated as to whether this effect might be ascribed to AG490-mediated suppression of ZIKV replication [<xref rid="ppat.1013457.ref019" ref-type="bibr">19</xref>]. In another experiment, knockdown of STAT1 decreased basal PD-L1 expression but only minimally affected ZIKV-induced PD-L1 production (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6B Fig</xref>). In addition, depletion of neither STAT1 (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6C Fig</xref>) nor JAK1 (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6D Fig</xref>) altered NS4B-induced PD-L1 expression. Thus, whereas JAK/STAT signaling modulates basal expression of PD-L1, it contributes minimally to ZIKV-induced PD-L1 production. These results lent further support to our model of the role of PD-L1 during ZIKV infection <italic toggle="yes">in vivo</italic>.</p></sec><sec id="sec007"><title>GRP78 interacts with NS4B to induce PD-L1 expression</title><p>To identify the host factors involved in NS4B-induced PD-L1 upregulation, we conducted mass spectrometric analysis to identify potential binding partners of NS4B. As shown in <xref rid="ppat.1013457.g006" ref-type="fig">Fig 6A</xref>, HSPA5, also known as glucose-regulated protein 78 (GRP78), an endoplasmic reticulum (ER) stress regulator, was identified as a binding partner of NS4B. In this regard, it is noteworthy that ZIKV infection triggers ER stress [<xref rid="ppat.1013457.ref045" ref-type="bibr">45</xref>,<xref rid="ppat.1013457.ref046" ref-type="bibr">46</xref>] and that GRP78 stabilizes PD-L1 in triple-negative breast cancer [<xref rid="ppat.1013457.ref047" ref-type="bibr">47</xref>].</p><fig position="float" id="ppat.1013457.g006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1013457.g006</object-id><label>Fig 6</label><caption><title>GRP78 interacts with NS4B to induce PD-L1 expression.</title><p><bold>(A)</bold> Volcano plot analysis of potential binding partners of NS4B. HSPA5 (GRP78) is highlighted with a red point. <bold>(B)</bold> Interaction between NS4B and GRP78. Immunoblot analysis of immunoprecipitates from HEK293T cells co-transfected with Flag-tagged NS4B and V5-tagged GRP78 expression plasmids. &#9082;-Tubulin was used as a loading control. <bold>(C)</bold> Western blot analysis of PD-L1, GRP78, Flag-NS4B and GAPDH expression levels in control or GRP78-silenced SF268 cells. (<bold>D</bold>) mRNA levels of PD-L1 were assessed using RT-qPCR. GAPDH was used as a housekeeping control. Western blot (<bold>E</bold>) and RT-qPCR (<bold>F</bold>) analysis of PD-L1 and ZIKV E expression in SF268 cells transfected with V5-GRP78 expression plasmids for 24 hours, followed by ZIKV infection for 48 hours. <bold>(G)</bold> Western blot analysis of PD-L1, GRP78 and ZIKV E protein in SF268 cells transfected with control or GRP78 siRNAs for 24 hours, followed by ZIKV infection for 48 hours. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed using Student&#8217;s t-test (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1013457.g006.jpg"/></fig><p>To validate the interaction between NS4B and GRP78, we performed reciprocal co-immunoprecipitation assays. GRP78 was detected in the NS4B precipitate, while NS4B was also found in the GRP78 precipitate (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6B</xref>). To investigate the role of GRP78 in NS4B-induced PD-L1 upregulation, we knocked down endogenous GRP78 in SF268 cells using siRNAs. The depletion of GRP78 abolished the enhanced PD-L1 expression at both the protein (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6C</xref>) and mRNA levels (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6D</xref>) in the presence of NS4B. Furthermore, overexpression of GRP78 further augmented PD-L1 expression following ZIKV infection (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6E</xref> and <xref rid="ppat.1013457.g006" ref-type="fig">6F</xref>). Consistent with this, knockdown of GRP78 led to a reduction in PD-L1 expression in ZIKV-infected cells (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6G</xref>). In addition, we observed that ZIKV infection induced an increase in GRP78 expression in SF268 cells (<xref rid="ppat.1013457.s007" ref-type="supplementary-material">S7A Fig</xref>). These findings were in line with the model in which GRP78 interacts NS4B (<xref rid="ppat.1013457.s007" ref-type="supplementary-material">S7B Fig</xref>) to upregulate PD-L1 expression.</p></sec></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>In this study, we provided evidence that ZIKV infection induces the expression of PD-L1 in cultured cells and <italic toggle="yes">in vivo</italic>. Blockade of PD-1/PD-L1 immune checkpoint using anti-PD-L1 antibody effectively restricted ZIKV infection, ascribed to robust virus-specific CD8<sup>+</sup> T cell response.</p><p>Recent studies have highlighted the critical roles of the PD-1/PD-L1 pathway in acute viral infection and pathogenesis [<xref rid="ppat.1013457.ref032" ref-type="bibr">32</xref>]. PD-1/PD-L1 expression increased in various immune cells upon infection with severe ever with thrombocytopenia syndrome virus (SFTSV). A novel anti-PD-1 nanobody named NbP45 effectively inhibited SFTSV infection in a humanized mouse model [<xref rid="ppat.1013457.ref048" ref-type="bibr">48</xref>]. Moreover, PD-L1 expression also elevated in cells infected with SARS-CoV-2 Omicron variant. In AAV-hACE2 mice infected with SARS-CoV-2, early PD-L1 blockade reduced proinflammatory cytokine levels and alleviated SARS-CoV-2-induced lymphopenia [<xref rid="ppat.1013457.ref049" ref-type="bibr">49</xref>]. Consistent with these and several other studies with similar findings [<xref rid="ppat.1013457.ref034" ref-type="bibr">34</xref>,<xref rid="ppat.1013457.ref035" ref-type="bibr">35</xref>], we demonstrated increased PD-L1 expression during ZIKV infection and the effective suppression of ZIKV infection using a PD-L1-blocking antibody. In addition, we identified a specific viral protein, NS4B, that upregulates PD-L1 expression, likely through an interaction with cellular chaperone GRP78.</p><p>The regulation of PD-L1 expression involves both transcriptional and post-translational mechanisms [<xref rid="ppat.1013457.ref050" ref-type="bibr">50</xref>,<xref rid="ppat.1013457.ref051" ref-type="bibr">51</xref>]. Various transcription factors and signaling pathways have been shown to modulate PD-L1 expression. IFNs are key regulators of PD-L1 expression. Both IFN-&#945;/&#946; and IFN-&#947; activate JAK-STAT signaling to drive PD-L1 transcription by IRF1 in various cell types, including immune cells and cancer cells [<xref rid="ppat.1013457.ref044" ref-type="bibr">44</xref>]. Thus, PD-L1 is a classical IFN-stimulated gene (ISG). Several crucial regulators of PD-L1 transcription, such as STAT3 and NF-&#954;B, are activated during viral infection [<xref rid="ppat.1013457.ref050" ref-type="bibr">50</xref>,<xref rid="ppat.1013457.ref051" ref-type="bibr">51</xref>]. Moreover, histone modifications like histone H3 lysine 4 trimethylation (H3K4me3) and acetylation in the PD-L1 promoter are also influential in transcriptional regulation of PD-L1 expression [<xref rid="ppat.1013457.ref052" ref-type="bibr">52</xref>]. On the other hand, PD-L1 stability and subcellular localization are modulated by post-translational modifications, including N-linked glycosylation, phosphorylation, ubiquitination and deubiquitination [<xref rid="ppat.1013457.ref050" ref-type="bibr">50</xref>,<xref rid="ppat.1013457.ref051" ref-type="bibr">51</xref>]. In our previous study, we demonstrated that ZIKV NS5 protein enhances IFN-&#947; activation and stimulates cellular proteins that drive inflammation, the known regulators of PD-L1 expression [<xref rid="ppat.1013457.ref019" ref-type="bibr">19</xref>]. However, in the current study, we did not observe any direct influence of NS5 on PD-L1 expression (<xref rid="ppat.1013457.g004" ref-type="fig">Fig 4A</xref> and <xref rid="ppat.1013457.g004" ref-type="fig">4D</xref>). Further analyses using a JAK-STAT inhibitor and the knockdown of STAT1 or JAK1 suggested that IFN signaling does not play a critical role in PD-L1 upregulation by ZIKV (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6 Fig</xref>). We found that both NS4A and NS4B of ZIKV can induce the expression of PD-L1 mRNA. Notably, the functions of flaviviral NS4A and NS4B in viral replication, membrane remodeling, immune evasion and pathogenesis are closely related [<xref rid="ppat.1013457.ref053" ref-type="bibr">53</xref>]. While the role of NS4B in upregulating PD-L1 at the transcriptional level is supported by its ability to enhance promoter activity likely in an IFN-independent manner (<xref rid="ppat.1013457.s006" ref-type="supplementary-material">S6D Fig</xref>), the mechanism by which NS4A upregulates PD-L1 expression remains unclear and awaits further investigations.</p><p>We found that ZIKV might induce PD-L1 expression through the interaction between NS4B and GRP78. GRP78 belongs to the heat shock protein 70 (HSP70) family [<xref rid="ppat.1013457.ref054" ref-type="bibr">54</xref>]. Primarily localized in the ER, GRP78 functions as a molecular chaperone, facilitating proper protein folding and preventing the accumulation of unfolded and misfolded proteins [<xref rid="ppat.1013457.ref055" ref-type="bibr">55</xref>]. Under normal physiological conditions, GRP78 maintains proteostasis within the ER. Upon ER stress, its expression is upregulated to meet increased demand of protein folding [<xref rid="ppat.1013457.ref056" ref-type="bibr">56</xref>]. Beyond the ER, GRP78 is also present on the cell surface as well as in the nucleus and mitochondria. It can also be secreted [<xref rid="ppat.1013457.ref057" ref-type="bibr">57</xref>].</p><p>ZIKV infection is known to induce ER stress. This is evidenced by the increased levels of ER stress markers observed during infection including GRP78 as indicated in our study. Sustained ER stress in ZIKV-infected cells leads to apoptosis [<xref rid="ppat.1013457.ref045" ref-type="bibr">45</xref>]. GRP78 has been implicated in the replication cycle of several flaviviruses, including dengue virus, Japanese encephalitis virus, and ZIKV [<xref rid="ppat.1013457.ref057" ref-type="bibr">57</xref>]. Notably, GRP78 has been shown to stabilize PD-L1 in triple-negative breast cancer [<xref rid="ppat.1013457.ref047" ref-type="bibr">47</xref>]. Interaction between GRP78 and other ZIKV proteins such as E and NS1 has also been reported [<xref rid="ppat.1013457.ref057" ref-type="bibr">57</xref>]. In this study, we identified an interaction between GRP78 and ZIKV NS4B, a viral protein with diverse roles in viral replication and immune evasion [<xref rid="ppat.1013457.ref058" ref-type="bibr">58</xref>]. Other interaction partners of NS4B such as VDAC2 and SLC25A1 identified by mass spectrometry are associated with cellular metabolic processes (<xref rid="ppat.1013457.g006" ref-type="fig">Fig 6A</xref>). We focused on GRP78 due to its role as an ER stress marker and its impact on PD-L1 regulation. We demonstrated a proviral role of GRP78 in SF268 cells. This aligns with findings from SARS-CoV-2 infection, where GRP78 acts as a proviral factor [<xref rid="ppat.1013457.ref059" ref-type="bibr">59</xref>]. Several studies have also shown that knockdown of GRP78 significantly reduces ZIKV production [<xref rid="ppat.1013457.ref060" ref-type="bibr">60</xref>&#8211;<xref rid="ppat.1013457.ref062" ref-type="bibr">62</xref>]. Our results suggest that GRP78 might serve as a critical link between ZIKV NS4B and PD-L1 upregulation. With the help of the AlphaFold program, we predicted the specific interaction domain and key amino acids in both NS4B and GRP78 (<xref rid="ppat.1013457.s007" ref-type="supplementary-material">S7B Fig</xref>). Further studies are needed to elucidate the precise mechanism by which NS4B and GRP78 regulate PD-L1 transcription and protein stability. In this regard, characterization of NS4B-deficient ZIKV constructed with an infectious clone could be insightful. It will also be of interest to identify natural variants of NS4B that exhibit differential activity in the interaction with GRP78 and the activation of PD-L1 expression. Notably, an NS4B mutant of ZIKV is severely attenuated and potently induces antiviral immunity including CD8<sup>+</sup> T cell response [<xref rid="ppat.1013457.ref063" ref-type="bibr">63</xref>]. It will be intriguing to determine whether GRP78 and PD-L1 might play any role in this phenotype.</p><p>Several mouse models have been developed for the study of ZIKV infection and pathogenesis [<xref rid="ppat.1013457.ref064" ref-type="bibr">64</xref>,<xref rid="ppat.1013457.ref065" ref-type="bibr">65</xref>]. Most of these models involve mice that lack a fully functional immune system. For example, A129 mice displayed severe symptoms following subcutaneous challenge in the lower leg to simulate a mosquito bite [<xref rid="ppat.1013457.ref040" ref-type="bibr">40</xref>]. AG129 mice that are deficient in both type I and type II IFN receptors can also be used. Whereas 3-week-old A129 and AG129 mice exhibited paralysis and succumbed by 7 dpi, older A129 mice of 11-week-old experienced weight loss and viremia but recovered after 8 dpi [<xref rid="ppat.1013457.ref066" ref-type="bibr">66</xref>,<xref rid="ppat.1013457.ref067" ref-type="bibr">67</xref>]. One major drawback of using immunocompromised mice is that they may not accurately reflect the natural immune response to ZIKV infection. Other studies have shown that ZIKV can infect WT C57BL/6 mice and trigger an antiviral T cell response, although resulting in only a mild decrease in body weight [<xref rid="ppat.1013457.ref023" ref-type="bibr">23</xref>]. For our study, we used 6&#8211;8-week-old A129 mice as the ZIKV infection model. It was based on our <italic toggle="yes">in vitro</italic> findings indicating that STAT1 or STAT3 signaling was not associated with ZIKV-induced PD-L1 upregulation, as well as the necessity to assess the efficacy of PD-L1-blocking antibody treatment. While a deficiency in type I IFN could compromise CD8<sup>+</sup> T cell response to viral infection [<xref rid="ppat.1013457.ref068" ref-type="bibr">68</xref>], our results demonstrated a robust virus-specific CD8<sup>+</sup> T cell response and improved functionality of CD8<sup>+</sup> T cells upon treatment with an anti-PD-L1 antibody, validating the suitability of our mouse model. Additionally, our data showed increased production of ZIKV-specific memory CD8<sup>+</sup> T cells in A129 mice treated with PD-1/PD-L1 antibodies. Collectively, these findings offer valuable insights into the development of a novel therapeutic approach against ZIKV infection.</p><p>Although the PD-L1 antibody-treated group showed a higher survival rate, the difference was not statistically significant. The IFN-&#945;/&#946; receptor deficiency in A129 mice confers extreme susceptibility to ZIKV infection in a lethal infection model [<xref rid="ppat.1013457.ref064" ref-type="bibr">64</xref>,<xref rid="ppat.1013457.ref065" ref-type="bibr">65</xref>]. The absence of type I IFN signaling enables uncontrolled viral replication, resulting in rapid disease progression that might render the comparison of survival differences between control and anti-PD-L1 treatment groups more difficult. In our study, we observed significant differences in clinical scores and viral loads between the two groups, despite similar mortality. Further optimization of the experimental settings including antibody dosage, virus strain and administration route, as in the case of <italic toggle="yes">Ifnar</italic><sup>-/-</sup> mice [<xref rid="ppat.1013457.ref069" ref-type="bibr">69</xref>,<xref rid="ppat.1013457.ref070" ref-type="bibr">70</xref>], might allow us to demonstrate the beneficial effect of PD-L1 blockade more convincingly.</p><p>Our demonstration of the activation of PD-L1 immune checkpoint by ZIKV raises several interesting questions that merit further investigations. First, it will be of interest to see whether the activation of PD-L1 immune checkpoint could be induced by other flaviviruses. If our findings with ZIKV can be generalized to other human flaviviral pathogens and other flaviviral NS4B proteins, they should have implications in the development of antivirals and vaccines. Second, the relevance of PD-L1 immune checkpoint to re-exposure should be addressed. CD8<sup>+</sup> T cell response is critical not only to ZIKV-na&#239;ve individuals, but also to people who have previously be exposed to or vaccinated against ZIKV and closely related flaviviruses such as Dengue virus, Japanese encephalitis virus and yellow fever virus. Cross-protective T cell response against these viruses has just begun to be understood [<xref rid="ppat.1013457.ref071" ref-type="bibr">71</xref>&#8211;<xref rid="ppat.1013457.ref073" ref-type="bibr">73</xref>]. Further analysis of the role of PD-L1 checkpoint in cross protection and re-exposure is warranted. Third, whether and how the PD-L1 checkpoint might affect vaccination and vaccine protection are related questions that require further analysis. The importance of CD8<sup>+</sup> T cell response in vaccine protection against flaviviruses has been documented [<xref rid="ppat.1013457.ref074" ref-type="bibr">74</xref>,<xref rid="ppat.1013457.ref075" ref-type="bibr">75</xref>]. Clarification of the role of PD-L1 checkpoint in this context might lead to new strategies in vaccine design. For example, whether immune checkpoint blockade might be of any benefit in vaccination should be determined.</p><p>One limitation of our study is the absence of clinical samples from ZIKV-infected individuals to assess PD-L1 expression. This is primarily due to the scarcity of imported cases of human ZIKV infection in our region. Furthermore, ascribed to the lack of humanized mouse models for ZIKV infection [<xref rid="ppat.1013457.ref064" ref-type="bibr">64</xref>,<xref rid="ppat.1013457.ref065" ref-type="bibr">65</xref>], our study did not include clinically approved PD-1/PD-L1 antibodies such as Nivolumab, Pembrolizumab and Tislelizumab. CD8<sup>+</sup> T cell response is cytotoxic by definition and could trigger pathogenic inflammation and tissue damage in the context of ZIKV infection [<xref rid="ppat.1013457.ref004" ref-type="bibr">4</xref>,<xref rid="ppat.1013457.ref005" ref-type="bibr">5</xref>]. Further investigations are required to explore the clinical significance and safety profile of immune checkpoint therapy targeting PD-1/PD-L1 during ZIKV infection. Particularly, since CD8<sup>+</sup> T cell response has been linked to ZIKV pathogenesis in the brain [<xref rid="ppat.1013457.ref026" ref-type="bibr">26</xref>] and other immune-privileged organs [<xref rid="ppat.1013457.ref076" ref-type="bibr">76</xref>], it will be of importance to verify that immune checkpoint blockade is free of severe side effects before any tests can be started in humans.</p></sec><sec sec-type="materials|methods" id="sec009"><title>Methods</title><sec id="sec010"><title>Ethics statement</title><p>The animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong (approval number: CULATR 24&#8211;087) and performed according to established safety protocols in the biosafety level 2 laboratory at the University of Hong Kong.</p></sec><sec id="sec011"><title>Viruses, plasmids and cells</title><p>ZIKV Puerto Rico strain PRVABC59 was obtained from the ATCC (VR-1843). For virus propagation, C6/36 cells grown for 24 hours were infected with ZIKV and maintained in DMEM with 2% FBS at 28&#176;C in a 5% CO<sub>2</sub> atmosphere. Virus was harvested on day 4 after infection and spun at 2,000&#8201;&#215;&#8201;g for 10 minutes to remove cell debris. The viral supernatant was aliquoted and frozen at -80&#176;C.</p><p>NS genes (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) of ZIKV were PCR amplified from PRVABC5 cDNA and cloned into the pcDNA5/FRT/TO or pCAGEN vector. pcDNA-GRP78-V5 were constructed as previously described [<xref rid="ppat.1013457.ref077" ref-type="bibr">77</xref>].</p><p>All cells were grown in the presence of 10% fetal calf serum (FCS) and 1% penicillin-streptomycin in a 5% CO<sub>2</sub> atmosphere. HEK293T, VeroE6 and SF268 cells were in Dulbecco&#8217;s modified Eagle&#8217;s medium at 37&#176;C. C6/36 cells were in the same medium at 28&#176;C. JEG3 cells were in minimum essential medium at 37&#176;C. Cells were transfected with Lipofectamine 3000 Transfection Reagent (ThermoFisher) or jetPRIME (Polyplus). The peripheral blood mononuclear cells (PBMCs) were isolated as described previously [<xref rid="ppat.1013457.ref078" ref-type="bibr">78</xref>]. GM-CSF and IL-4 were used to induce dendritic cell differentiation.</p></sec><sec id="sec012"><title>Antibodies</title><p>The following antibodies were used for Western blotting: mouse monoclonal anti-Flag antibody M2 (Sigma, F1804), flavivirus group antigen antibody (Novus Biologicals, NBP2&#8211;52709), recombinant rabbit monoclonal anti-PD-L1 antibody (Abcam, ab205921), rabbit anti-GRP78 (Abcam, ab21685), mouse monoclonal anti-&#945;-tubulin antibody (Sigma, T5168), anti-GAPDH antibody (Santa Cruz, sc-47724) and anti-&#946;-actin antibody (Santa Cruz, sc-8432). A recombinant mouse monoclonal anti-PD-L1 antibody, designated anti-PD-L1-mIgG1e3 or Azeto (InvivoGen, pdl1-mab15&#8211;10), was employed for PD-L1 blockade in mice.</p></sec><sec id="sec013"><title>Viral infection</title><p>SF268 or JEG3 cells were infected with ZIKV at an MOI of 1.0 or 0.1. Following a 1-hour incubation at 37&#176;C, the cells were washed at least twice with PBS and then incubated in DMEM containing 2% FCS. Cell lysates or supernatants were collected at the specified time points post-infection. Three independent experiments were performed.</p></sec><sec id="sec014"><title>Plaque assay</title><p>Confluent VeroE6 cells were seeded in a 12-well plate and incubated with 10-fold serial dilutions of ZIKV for 1 hour. After adsorption to VeroE6 cells, the viral supernatant was removed, and the cells were washed three times with PBS before being overlaid with 1% low melting point agarose in DMEM. The cells were then incubated at 37&#176;C for 4 days, fixed with 10% formaldehyde overnight, and subsequently stained with 1% crystal violet to visualize and count the plaques for determining viral titers.</p></sec><sec id="sec015"><title>Western blotting and co-immunoprecipitation</title><p>Western blotting was performed as described previously [<xref rid="ppat.1013457.ref079" ref-type="bibr">79</xref>]. In brief, cells were directly lysed in lysis buffer (50&#8201;mM Tris-Cl at pH 7.4, 150&#8201;mM NaCl, 1% NP-40, 5&#8201;mM EDTA, 1&#8201;&#215;&#8201;complete protease inhibitor cocktail, and 10% glycerol) which mixed with SDS sample buffer. Cells were sonicated and boiled. The protein samples were resolved by SDS-PAGE and then transferred onto a polyvinylidene difluoride membrane. The membranes were blocked with 5% skimmed milk in TBST (TBS containing 0.5% Tween 20) for 1 hour at room temperature and then incubated with primary antibodies overnight at 4&#176;C, followed by an incubation with secondary antibodies for 1 hour at room temperature. The reactive protein bands were visualized using an enhanced chemiluminescence reagent (ThermoFisher, 34580) with a ChemiDoc Imaging System (Bio-Rad). Co-immunoprecipitation was performed as described previously [<xref rid="ppat.1013457.ref080" ref-type="bibr">80</xref>]. In brief, cells were lysed in lysis buffer and cell lysates were incubated with anti-Flag M2 beads (Sigma-Aldrich) for 2&#8211;4 hours at 4&#730;C. The beads were then washed three times and boiled. Protein samples were analyzed by Western blotting.</p></sec><sec id="sec016"><title>RNA extraction and quantitative reverse transcription PCR (RT&#8211;qPCR)</title><p>RNA extraction, reverse transcription, and qPCR were performed as previously described [<xref rid="ppat.1013457.ref081" ref-type="bibr">81</xref>]. Briefly, total RNA was extracted from cells or mouse organs (brain, testis, and spleen) with a RNeasy Mini Kit (Qiagen, Germantown, MD, USA) and reverse-transcribed with a PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time, Takara, R0047) or One-Step TB Green PrimeScript RT-PCR Kit (Perfect Real Time, Takara, R0086). Real-time PCR was performed using ChamQ SYBR Color qPCR Master Mix (Vazyme, Q411-02) and a CFX96 Touch Deep Well Real-Time PCR Detection System (Bio&#8211;Rad, Berkeley, California, USA) according to the manufacturer&#8217;s instructions. The primers used were listed below: 5&#8242;-TGGCATTTG CTGAACGCAT TT and 5&#8242;-TGCAGCCAGG TCTAATTGTT TT for human PD-L1; 5&#8242;- AGAAGGCTGG GGCTCATT TG and 5&#8242;-CTGTGGTCAT GAGTCCTTC for human GAPDH; 5&#8242;-CATGGCTTCT GACAGCCGCT and 5&#8242;-TGGATGCTCT TCCCGGTCAT TTT for ZIKV E as well as 5&#8242;- AGGTCGGTGT GAACGGATTT G and 5&#8242;-GGGGTCGTTG ATGGCAACA for mouse GAPDH. Relative gene expression was determined either through normalization to the corresponding Ct values for GAPDH and calculated using the 2<sup>-&#916;&#916;Ct</sup> method.</p></sec><sec id="sec017"><title>Evaluation of the effect of PD-L1 blockade on ZIKV infection <italic toggle="yes">in vivo</italic></title><p>The type I IFN receptor-deficient A129 mouse model was utilized for ZIKV infection as previously described [<xref rid="ppat.1013457.ref046" ref-type="bibr">46</xref>,<xref rid="ppat.1013457.ref082" ref-type="bibr">82</xref>,<xref rid="ppat.1013457.ref083" ref-type="bibr">83</xref>]. In brief, 6&#8211;8 week-old A129 male mice were randomly split into three groups. The mice were inoculated i.p. with 3&#8201;&#215;&#8201;10<sup>3</sup> PFU of ZIKV at a final volume of 100 &#956;L. The mice were i.p. treated with 200 &#956;g isotype control (anti-&#946;-Gal-mIgG1e3, InvivoGen) or anti-PD-L1 antibody (anti-PD-L1-mIgG1e3 or Azeto, InvivoGen, pdl1-mab15&#8211;10) at a final volume of 100 &#956;L on days 1, 3, 5 and 7 post-infection. Mock treatment was used as control. The mice were euthanized on day 8 post-virus challenge for sample harvest. Alternatively, the mice were euthanized for humane end points when there was a&#8201;&gt;&#8201;20% weight loss. During sample harvest, the brain and testis of mice were collected for viral load studies, and the spleen of mice were also used for splenocyte isolation. Mice were monitored each day for clinical signs and a numerical score was assigned at each observation as previously described (0, normal; 2, ruffled fur; 3, lethargy, pinched, hunched, wasp waisted; 5, laboured breathing, rapid breathing, inactive, neurological; and 10, immobile) [<xref rid="ppat.1013457.ref040" ref-type="bibr">40</xref>]. Body weight and survival were monitored daily for 14 dpi or until euthanasia.</p></sec><sec id="sec018"><title>Flow cytometry</title><p>Splenocytes were isolated and filtered through a 70-&#956;m cell strainer (Falcon) and then resuspended in RC-10 medium (RPMI 1640 medium supplemented with 10% FCS, 2mM L-glutamine, 100 U/ml penicillin, 100&#8201;mg/ml streptomycin, 50&#8201;mM 2-mercaptoethanol and 10mM HEPES). Red blood cells were lysed using Red Blood Cell Lysing Buffer (Sigma, R7757). Cells were treated with the 2.4G2 monoclonal antibody (anti-CD16/32) to block Fc receptors. To exclude dead cells from the staining results, Zombie Aqua Fixable Viability Kit (Biolegend, 423102) was used according to the manufacturer&#8217;s instructions. The following antibodies against mouse antigens were used: FC block (BioLegend 156604), anti-CD4 (PerCP-Cy5.5, BioLegend 116012), anti-CD8 (BV421, BioLegend 100753), anti-CD44 (BV711, BioLegend 103057), anti-KLRG1 (APC, BioLegend 138412), anti-CD62L (PE-Cy7, BioLegend 104418), anti-PD-1 (PE, BioLegend 135205), anti-CD107a (A488, BioLegend 121608), anti-IFN-&#947; (PE-Cy7, BioLegend 505825), anti-TNF-&#945; (BV785, BioLegend 506341), anti-IL-2 (APC, BioLegend 503810) and anti-granzyme B (PE, BioLegend 396406). Antigen-specific CD8<sup>+</sup> T cells were detected using ZIKV-specific textramers (Immudex). For intracellular cytokine staining, a total of 1&#8201;&#215;&#8201;10<sup>6</sup> splenocytes were plated in each well of 96-well U-bottom plates and stimulated with individual peptide (E<sub>4-12</sub>: IGVSNRDFV and NS3<sub>206&#8211;215</sub>: APTRVVAAEM). Peptides were synthesized at GL Biochem (Shanghai, China) with 95% purity. Splenocytes stimulated with PMA-ionomycin were used as a positive control. After 1 hour, brefeldin A (GolgiPlug, BD Biosciences) was added to the cells, and the cells were incubated for 5 hours at 37&#176;C. A BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (BD Bioscience) was then used according to the manufacturer&#8217;s instructions. All samples were acquired on an LSR Fortessa flow cytometer (BD Biosciences, USA), and the data were analyzed with FlowJo software.</p></sec><sec id="sec019"><title>Luciferase reporter activity of PD&#8208;L1 promoter</title><p>Genome DNA was extracted using the Quick-DNA Miniprep Plus Kit (Zymo Research). The PD-L1 promoter was generated through PCR amplification. The resulting PCR product was purified with the FastPure Gel DNA Extraction Mini Kit (Vazyme) and then inserted into the pGL3-basic firefly luciferase vector. In the reporter assays, HEK293T cells were co-transfected with the ZIKV NS gene, the PD-L1 promoter, and the Renilla construct using the GeneJuice Transfection Reagent (Sigma). At 24 hours post-transfection, luciferase activity was assessed using the Dual-Luciferase Reporter Assay System kit (Promega).</p></sec><sec id="sec020"><title>RNA interference</title><p>siRNAs against GRP78 were transfected using Lipofectamine 3000 (Invitrogen) at a final concentration of 75 pmol for 2 consecutive days in 6-well plates following the manufacturer&#8217;s instructions. siRNAs against GRP78 (5&#8242;- UCUACAGCUU CUGAUAAUCA ACCAA) are constructed by Integrated DNA Technologies.</p></sec><sec id="sec021"><title>Proteomics</title><p>To identify NS4B-binding proteins, NS4B and its binding proteins were precipitated with Anti-Flag M2 agarose beads from HEK293T cells stably expressing Flag-NS4B. After washing five times with 20&#8201;mM ammonium bicarbonate (pH:7.8), 10&#8201;mM DTT in 100&#8201;mM ammonium bicarbonate (pH:7.8) was added to the beads for reduction in a 37&#176;C shaker for 30&#8201;min. Then, alkylation was performed by adding an equal volume of 25&#8201;mM iodoacetamide to the DTT bead suspension and rotating in the dark for 30 minutes at room temperature. Proteins were then digested by trypsin (1:100 enzyme/substrate ratio, 37&#176;C shaker, overnight). Peptides were desalted with C18 Toptip and then dried in a rotary evaporator.</p><p>Purified peptides were re-suspended in 0.1% formic acid for LC-MS run. Briefly, peptides separated with the C18 Acclaim PepMap column (75 &#956;m id&#8201;&#215;&#8201;15&#8201;cm, 2 &#956;m particle sizes, 100 &#197; pore sizes, Thermo Scientific) were ionized at 1.9&#8201;kV in the positive ion mode. MS1 survey scans were acquired at the resolution of 70,000 from 350 to 1800 m/z, with a maximum injection time of 100&#8201;ms and automated gain control (AGC) target of 1e6. MS/MS fragmentation of the 14 most abundant ions were analyzed at a resolution of 17,500, AGC target 5e4, maximum injection time 65&#8201;ms, and normalized collision energy of 26. Dynamic exclusion was set to 20&#8201;s and ions with a charge of +1,&#8201;+&#8201;7 and&gt;+7 was excluded. MS/MS fragmentation spectra were searched with Proteome Discoverer SEQUEST (version 2.4, Thermo Scientific) against the in silico tryptic digested Uniprot all-reviewed Homo sapiens database (release June 2017, 42,140 entries). The maximum missed cleavages were set to 3. Dynamic modifications were set to oxidation on methionine (M,&#8201;+&#8201;15.995&#8201;Da) and deamidation on asparagine and glutamine (N and Q,&#8201;+&#8201;0.984&#8201;Da). Carbamidomethylation on cysteine residues (C,&#8201;+&#8201;57.021&#8201;Da) was set as a fixed modification. The maximum parental mass error was set to 10&#8201;ppm, and the MS/MS mass tolerance was set to 0.03&#8201;Da. The false discovery threshold was set strictly to 0.01 using the Percolator Node validated by q-value. The relative abundance of parental peptides was calculated by integration of the area under the curve of the MS1 peaks using the Minora LFQ node. Spectral annotation was generated by the Interactive Peptide Spectral Annotator (IPSA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www" ext-link-type="uri">http://www</ext-link>. interactivepeptidespectralannotator.com/). The mass spectrometry data have been deposited into the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD062250 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/" ext-link-type="uri">https://www.ebi.ac.uk/pride/archive/projects/</ext-link> PXD062250).</p></sec><sec id="sec022"><title>RNA-seq data analysis</title><p>RNA-seq data from JEG3, U-251 MG and HK-2 cells infected with ZIKV were retrieved from NCBI Gene Expression Omnibus [<xref rid="ppat.1013457.ref038" ref-type="bibr">38</xref>]. DEGs were detected by two-tailed Student&#8217;s t-test by comparing with corresponding mock infection. In each group, those genes with P values less than 0.05 and FC larger than 1.5 or less than 0.5 were detected as DEGs. DEGs were enriched through Gene Ontology Biological Process (GO BP) .</p></sec></sec><sec id="sec023" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ppat.1013457.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Fig</label><caption><title>RNA-seq data for JEG3, U-251 MG and HK-2 cells infected with ZIKV.</title><p>(<bold>A</bold>) DEGs in placental cells (JEG-3), nerve cells (U-251 MG) and kidney cells (HK-2) retrieved from the publicly available datasets. In each group, those genes with P values less than 0.05 and fold change larger than 1.5 or less than 0.5 were detected as DEGs. (<bold>B</bold>) Gene Ontology Biological Processes (GO BP) analysis of the 92 common DEGs. (<bold>C</bold>) A heatmap depicting the expression of 92 common DEGs across JEG-3, U-251 MG and HK-2 cells. Rows represent genes, and columns represent samples obtained from the three cell lines: JEG-3 cells, U-251 MG cells and HK-2 cells. Each cell line includes both non-infected and ZIKV-infected groups, with three experiments conducted for each sample. The numerical values in the heatmap represent the logarithm of the expression value&#8201;+&#8201;1.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s001.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s002" position="float" content-type="local-data" orientation="portrait"><label>S2 Fig</label><caption><title>ZIKV infection upregulates PD-L1 expression in JEG3 cells.</title><p>Flow cytometric analysis of PD&#8208;L1 in JEG3 cells upon ZIKV infection. JEG3 cells were infected with ZIKV strain PRVABC59 for 48 hours and were analyzed for the expression of PD-L1 (gated on live cells) (<bold>A</bold>), quantification of the frequency of PD-L1 positive cells (<bold>B</bold>), quantification of the mean fluorescence intensity (MFI) of PD-L1 using flow cytometry (<bold>C</bold>). The results are shown as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed with one-way ANOVA (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s002.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s003" position="float" content-type="local-data" orientation="portrait"><label>S3 Fig</label><caption><title>ZIKV Uganda strain upregulates PD-L1 expression in cultured cells.</title><p>SF268 cells (<bold>A</bold>) and JEG3 cells (<bold>B</bold>) were infected with ZIKV AF-976 Uganda strain at a MOI of 1. Cell lysates were collected at 24, 48 and 72 hpi. The mRNA levels of PD-L1 were assessed using RT-qPCR. GAPDH was used as a housekeeping control. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed by two-way ANOVA (***P&#8201;&lt;&#8201;0.001). Protein levels of PD-L1 and ZIKV E were assessed by Western blotting with GAPDH as a loading control.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s003.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s004" position="float" content-type="local-data" orientation="portrait"><label>S4 Fig</label><caption><title>Impact of PD-L1 blockade on clinical signs and survival of A129 mice.</title><p>(<bold>A</bold>) Antibody treatment and viral challenge scheme for the A129 model for survival. Male A129 mice (n&#8201;=&#8201;8/group) were i.p. inoculated with 2&#8201;&#215;&#8201;10&#179; PFU of ZIKV and subsequently i.p. treated with 150 &#956;g of either IgG control or anti-PD-L1 antibody on 2, 4, 6, and 8 dpi. Body weight changes in mice over a 14-day period were observed. The figure was created using BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">https://BioRender.com</ext-link>). (<bold>B</bold>) Clinical scores of A129 mice. The results are shown as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed with two-way ANOVA (*P&#8201;&lt;&#8201;0.05; **P&#8201;&lt;&#8201;0.01; ***P&#8201;&lt;&#8201;0.001). (<bold>C</bold>) Survival rate of mice. Mice that lost more than 20% of their basal weight were euthanized.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s004.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s005" position="float" content-type="local-data" orientation="portrait"><label>S5 Fig</label><caption><title>PD-L1 inhibition does not significantly affect ZIKV infection <italic toggle="yes">in vitro.</italic></title><p>(<bold>A</bold>) U251 cells were transfected with control or PD-L1 siRNA for 24 hours, followed by ZIKV infection for 48 hours. Protein levels of PD-L1 and E protein were assessed by Western blotting with GAPDH as a loading control. (<bold>B</bold>) ZIKV RNA levels in the supernatant of infected cells were detected by one-step RT-qPCR. Statistical analyses were performed with one-way ANOVA. (<bold>C</bold>) SF268 cells were transfected with increasing dose of PD-L1. Protein levels of PD-L1 and E protein were assessed by Western blotting with &#9082;-tubulin as a loading control. Results are representative of three independent experiments. (<bold>D</bold>) SF268 and U251 cells were infected with ZIKV at an MOI of 1. After 1 hour, the medium was replaced with 2% DMEM containing either IgG control (&#945;IgG) or anti-PD-L1 (&#945;PD-L1; Azeto) at 2 &#181;g/ml. Viral RNA levels in the supernatant were quantified by one-step RT-qPCR at 24 hpi. Statistical significance was determined using Student&#8217;s t-test. <bold>(E)</bold> SF268 cells were infected with ZIKV at an MOI of 1. After a 1-hour incubation, the medium was replaced with 2% DMEM containing either PD-1/PD-L1 inhibitor 1 (BMS-1, 1 &#956;M) or PD-1/PD-L1 inhibitor 3 (2 &#956;M). Cell lysates were collected at 48 hpi. The mRNA levels of PD-L1 were assessed using RT-qPCR. GAPDH was used as a housekeeping control. Data are presented as the mean&#8201;&#177;&#8201;SD of three independent experiments. Statistical analyses were performed by two-way ANOVA. <bold>(F)</bold> ZIKV RNA levels in the supernatant of infected cells were detected by one-step RT-qPCR. Statistical analyses were performed with one-way ANOVA.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s005.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s006" position="float" content-type="local-data" orientation="portrait"><label>S6 Fig</label><caption><title>Influence of JAK/STAT inhibition on ZIKV-induced PD-L1 expression <italic toggle="yes">in vitro.</italic></title><p>(<bold>A</bold>) Effect of AG490 on ZIKV-induced PD-L1 expression. SF268 cells were infected with ZIKV at an MOI of 1 for 24 hours and then treated with 50 &#956;M AG490 for 12 hours. Western blot analysis of PD-L1, STAT3, pSTAT3 and ZIKV E protein in SF268 cells was performed with GAPDH as a loading control. Effect of STAT1 knockdown on PD-L1 expression induced by ZIKV (<bold>B</bold>) and NS4B (<bold>C</bold>). Western blot analysis of PD-L1, STAT1, ZIKV E/Flag-NS4B and GAPDH/&#945;-tubulin expression levels in control or STAT1-silenced SF268 cells was performed. (<bold>D</bold>) Effect of JAK1 knockdown on NS4B-induced PD-L1 expression. Western blot analysis of PD-L1, JAK1, Flag-NS4B and &#945;-tubulin expression levels in control or JAK1-silenced SF268 cells was performed.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s006.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ppat.1013457.s007" position="float" content-type="local-data" orientation="portrait"><label>S7 Fig</label><caption><title>GRP78 induces PD-L1 expression during ZIKV infection.</title><p>(<bold>A</bold>) Western blot analysis of PD-L1, GRP78 and ZIKV E protein in SF268 cells after ZIKV infection for 24, 48 and 72 hours. (<bold>B</bold>) AlphaFold analysis of the specific interaction domain and key amino acid site in both NS4B and GRP78. Blue: NS4B, pink: GRP78.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ppat.1013457.s007.tif" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>We thank members of Jin lab for critical reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="ppat.1013457.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pierson</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Diamond</surname><given-names>MS</given-names></name>. <article-title>The continued threat of emerging flaviviruses</article-title>. <source>Nat Microbiol</source>. <year>2020</year>;<volume>5</volume>(<issue>6</issue>):<fpage>796</fpage>&#8211;<lpage>812</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-020-0714-0</pub-id><pub-id pub-id-type="pmid">32367055</pub-id><pub-id pub-id-type="pmcid">PMC7696730</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sakkas</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bozidis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Giannakopoulos</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sofikitis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Papadopoulou</surname><given-names>C</given-names></name>. <article-title>An update on sexual transmission of Zika virus</article-title>. <source>Pathogens</source>. <year>2018</year>;<volume>7</volume>:<fpage>66</fpage>.&#160;<pub-id pub-id-type="doi">10.3390/pathogens7030066</pub-id><pub-id pub-id-type="pmid">30081445</pub-id><pub-id pub-id-type="pmcid">PMC6161238</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ades</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Thorne</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Soriano-Arandes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Peckham</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Researching Zika in pregnancy: lessons for global preparedness</article-title>. <source>Lancet Infect Dis</source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):e61&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30021-9</pub-id><pub-id pub-id-type="pmid">32085848</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shahrizaila</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lehmann</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Kuwabara</surname><given-names>S</given-names></name>. <article-title>Guillain-Barr&#233; syndrome</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10280</issue>):<fpage>1214</fpage>&#8211;<lpage>28</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00517-1</pub-id><pub-id pub-id-type="pmid">33647239</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Giraldo</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Gonzalez-Orozco</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rajsbaum</surname><given-names>R</given-names></name>. <article-title>Pathogenesis of Zika virus infection</article-title>. <source>Annu Rev Pathol</source>. <year>2023</year>;<volume>18</volume>:<fpage>181</fpage>&#8211;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-031521-034739</pub-id>&#160;<pub-id pub-id-type="pmid">36151059</pub-id><pub-id pub-id-type="pmcid">PMC10893765</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ngono</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Shresta</surname><given-names>S</given-names></name>. <article-title>Immune Response to Dengue and Zika</article-title>. <source>Annu Rev Immunol</source>. <year>2018</year>;<volume>36</volume>:<fpage>279</fpage>&#8211;<lpage>308</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053142</pub-id><pub-id pub-id-type="pmid">29345964</pub-id><pub-id pub-id-type="pmcid">PMC5910217</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>da Silva</surname><given-names>MHM</given-names></name>, <name name-style="western"><surname>Moises</surname><given-names>RNC</given-names></name>, <name name-style="western"><surname>Alves</surname><given-names>BEB</given-names></name>, <name name-style="western"><surname>Pereira</surname><given-names>HWB</given-names></name>, <name name-style="western"><surname>de Paiva</surname><given-names>AAP</given-names></name>, <name name-style="western"><surname>Morais</surname><given-names>IC</given-names></name>, <etal>et al</etal>. <article-title>Innate immune response in patients with acute Zika virus infection</article-title>. <source>Med Microbiol Immunol</source>. <year>2019</year>;<volume>208</volume>:<fpage>703</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s00430-019-00588-8</pub-id><pub-id pub-id-type="pmid">30879197</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Savidis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Perreira</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Portmann</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Meraner</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>The IFITMs Inhibit Zika Virus Replication</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>15</volume>(<issue>11</issue>):<fpage>2323</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.074</pub-id><pub-id pub-id-type="pmid">27268505</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Elong Ngono</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vizcarra</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Sheets</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Joo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice</article-title>. <source>Cell Host Microbe</source>. <year>2017</year>;<volume>21</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2016.12.010</pub-id><pub-id pub-id-type="pmid">28081442</pub-id><pub-id pub-id-type="pmcid">PMC5234855</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins in vitro</article-title>. <source>Cell Discov</source>. <year>2017</year>;<volume>3</volume>:<fpage>17006</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/celldisc.2017.6</pub-id><pub-id pub-id-type="pmid">28373913</pub-id><pub-id pub-id-type="pmcid">PMC5359216</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis</article-title>. <source>EMBO J</source>. <year>2018</year>;<volume>37</volume>(<issue>18</issue>):e99347. <comment>doi: </comment><pub-id pub-id-type="doi">10.15252/embj.201899347</pub-id><pub-id pub-id-type="pmid">30065070</pub-id><pub-id pub-id-type="pmcid">PMC6138430</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fanunza</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Carletti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Quartu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grandi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ermellino</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Milia</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Zika virus NS2A inhibits interferon signaling by degradation of STAT1 and STAT2</article-title>. <source>Virulence</source>. <year>2021</year>;<volume>12</volume>:<fpage>1580</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1080/21505594.2021.1935613</pub-id><pub-id pub-id-type="pmid">34338586</pub-id><pub-id pub-id-type="pmcid">PMC8331042</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ding</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Gaska</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Douam</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Balev</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>27</issue>):E6310&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1803406115</pub-id><pub-id pub-id-type="pmid">29915078</pub-id><pub-id pub-id-type="pmcid">PMC6142274</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Zika virus circumvents host innate immunity by targeting the adaptor proteins MAVS and MITA</article-title>. <source>FASEB Journal</source>. <year>2019</year>;<volume>33</volume>:<fpage>9929</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201900260R</pub-id><pub-id pub-id-type="pmid">31180720</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Riedl</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Acharya</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J-H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Serman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chiang</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity</article-title>. <source>Cell Host Microbe</source>. <year>2019</year>;<volume>26</volume>(<issue>4</issue>):493-503.e6. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2019.09.012</pub-id><pub-id pub-id-type="pmid">31600501</pub-id><pub-id pub-id-type="pmcid">PMC6922055</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>X</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Zika virus antagonizes interferon response in patients and disrupts RIG-I-MAVS interaction through its CARD-TM domains</article-title>. <source>Cell Biosci</source>. <year>2019</year>;<volume>9</volume>:<fpage>46</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13578-019-0308-9</pub-id><pub-id pub-id-type="pmid">31183075</pub-id><pub-id pub-id-type="pmcid">PMC6555941</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fanunza</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Grandi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Quartu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carletti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ermellino</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Milia</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>INMI1 Zika Virus NS4B Antagonizes the Interferon Signaling by Suppressing STAT1 Phosphorylation</article-title>. <source>Viruses</source>. <year>2021</year>;<volume>13</volume>(<issue>12</issue>):<fpage>2448</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/v13122448</pub-id><pub-id pub-id-type="pmid">34960717</pub-id><pub-id pub-id-type="pmcid">PMC8705506</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sarratea</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Alberti</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Redolfi</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Truant</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Iannantuono Lopez</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Bivona</surname><given-names>AE</given-names></name>, <etal>et al</etal>. <article-title>Zika virus NS4B protein targets TANK-binding kinase 1 and inhibits type I interferon production</article-title>. <source>Biochim Biophys Acta Gen Subj</source>. <year>2023</year>;<volume>1867</volume>(<issue>12</issue>):<fpage>130483</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbagen.2023.130483</pub-id><pub-id pub-id-type="pmid">37802371</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grant</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ponia</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Tripathi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balasubramaniam</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Miorin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sourisseau</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Zika virus targets human STAT2 to inhibit type I interferon signaling</article-title>. <source>Cell Host Microbe</source>. <year>2016</year>;<volume>19</volume>:<fpage>882</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.05.009</pub-id><pub-id pub-id-type="pmid">27212660</pub-id><pub-id pub-id-type="pmcid">PMC4900918</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chaudhary</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>K-S</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>JF-W</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>C-P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P-H</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J-P</given-names></name>, <etal>et al</etal>. <article-title>Selective Activation of Type II Interferon Signaling by Zika Virus NS5 Protein</article-title>. <source>J Virol</source>. <year>2017</year>;<volume>91</volume>(<issue>14</issue>):e00163-17. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.00163-17</pub-id><pub-id pub-id-type="pmid">28468880</pub-id><pub-id pub-id-type="pmcid">PMC5487581</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Zika virus NS5 protein inhibits type I interferon signaling via CRL3 E3 ubiquitin ligase-mediated degradation of STAT2</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2024</year>;<volume>121</volume>(<issue>34</issue>):e2403235121. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2403235121</pub-id><pub-id pub-id-type="pmid">39145933</pub-id><pub-id pub-id-type="pmcid">PMC11348293</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bowen</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Quicke</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Maddur</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>O&#8217;Neal</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Fedorova</surname><given-names>NB</given-names></name>, <etal>et al</etal>. <article-title>Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells</article-title>. <source>PLoS Pathog</source>. <year>2017</year>;<volume>13</volume>(<issue>2</issue>):e1006164. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1006164</pub-id><pub-id pub-id-type="pmid">28152048</pub-id><pub-id pub-id-type="pmcid">PMC5289613</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tonnerre</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Melga&#231;o</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Torres-Cornejo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pinto</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bl&#252;mel</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Evolution of the innate and adaptive immune response in women with acute Zika virus infection</article-title>. <source>Nat Microbiol</source>. <year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>76</fpage>&#8211;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-019-0618-z</pub-id><pub-id pub-id-type="pmid">31792427</pub-id><pub-id pub-id-type="pmcid">PMC6938397</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pardy</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Rajah</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Condotta</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Sagan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Richer</surname><given-names>MJ</given-names></name>. <article-title>Analysis of the T Cell Response to Zika Virus and Identification of a Novel CD8+ T Cell Epitope in Immunocompetent Mice</article-title>. <source>PLoS Pathog</source>. <year>2017</year>;<volume>13</volume>(<issue>2</issue>):e1006184. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1006184</pub-id><pub-id pub-id-type="pmid">28231312</pub-id><pub-id pub-id-type="pmcid">PMC5322871</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>CD8+ T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection</article-title>. <source>J Virol</source>. <year>2017</year>;<volume>91</volume>(<issue>22</issue>):e00900-17. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.00900-17</pub-id><pub-id pub-id-type="pmid">28835502</pub-id><pub-id pub-id-type="pmcid">PMC5660488</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Costa-Ramos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rosales</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Seumois</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Cutting edge: Transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of Zika virus-specific CD8 T cells</article-title>. <source>J Immunol</source>. <year>2018</year>;<volume>201</volume>:<fpage>3487</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1801090</pub-id><pub-id pub-id-type="pmid">30413672</pub-id><pub-id pub-id-type="pmcid">PMC6287102</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Balint</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Giles</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Vahedi</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Bystander activated CD8+ T cells mediate neuropathology during viral infection via antigen-independent cytotoxicity</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>896</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-023-44667-0</pub-id><pub-id pub-id-type="pmid">38316762</pub-id><pub-id pub-id-type="pmcid">PMC10844499</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lazear</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Govero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Platt</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Miner</surname><given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>A Mouse Model of Zika Virus Pathogenesis</article-title>. <source>Cell Host Microbe</source>. <year>2016</year>;<volume>19</volume>(<issue>5</issue>):<fpage>720</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2016.03.010</pub-id><pub-id pub-id-type="pmid">27066744</pub-id><pub-id pub-id-type="pmcid">PMC4866885</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jurado</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Yockey</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huttner</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name>. <article-title>Antiviral CD8 T cells induce Zika-virus-associated paralysis in mice</article-title>. <source>Nat Microbiol</source>. <year>2018</year>;<volume>3</volume>(<issue>2</issue>):<fpage>141</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-017-0060-z</pub-id><pub-id pub-id-type="pmid">29158604</pub-id><pub-id pub-id-type="pmcid">PMC5780207</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pardy</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Valbon</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Cordeiro</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Krawczyk</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Richer</surname><given-names>MJ</given-names></name>. <article-title>An epidemic Zika virus isolate suppresses antiviral immunity by disrupting antigen presentation pathways</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>4051</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-24340-0</pub-id><pub-id pub-id-type="pmid">34193875</pub-id><pub-id pub-id-type="pmcid">PMC8245533</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yaguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tajima</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Honjo</surname><given-names>T</given-names></name>. <article-title>Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1</article-title>. <source>Nat Rev Immunol</source>. <year>2023</year>;<volume>23</volume>(<issue>10</issue>):<fpage>682</fpage>&#8211;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41577-023-00867-9</pub-id><pub-id pub-id-type="pmid">37185300</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Goswami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Raychaudhuri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Siddiqui</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nagarajan</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Immune checkpoint therapy-current perspectives and future directions</article-title>. <source>Cell</source>. <year>2023</year>;<volume>186</volume>(<issue>8</issue>):<fpage>1652</fpage>&#8211;<lpage>69</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.006</pub-id><pub-id pub-id-type="pmid">37059068</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sch&#246;nrich</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Raftery</surname><given-names>MJ</given-names></name>. <article-title>The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2019</year>;<volume>9</volume>:<fpage>207</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fcimb.2019.00207</pub-id><pub-id pub-id-type="pmid">31263684</pub-id><pub-id pub-id-type="pmcid">PMC6584848</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schmitt</surname><given-names>MER</given-names></name>, <name name-style="western"><surname>Sitte</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Voehringer</surname><given-names>D</given-names></name>. <article-title>CD4 T Helper Cells Instruct Lymphopenia-Induced Memory-Like CD8 T Cells for Control of Acute LCMV Infection</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:<fpage>622</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2016.00622</pub-id><pub-id pub-id-type="pmid">28066432</pub-id><pub-id pub-id-type="pmcid">PMC5174106</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Erickson</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Gilchuk</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hastings</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Tollefson</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Downing</surname><given-names>MB</given-names></name>, <etal>et al</etal>. <article-title>Viral acute lower respiratory infections impair CD8 T cells through PD-1</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>:<fpage>2967</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1172/JCI62860</pub-id><pub-id pub-id-type="pmid">22797302</pub-id><pub-id pub-id-type="pmcid">PMC3408742</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rutigliano</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Oguin</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>McClaren</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Doherty</surname><given-names>PC</given-names></name>, <etal>et al</etal>. <article-title>Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8 T cells</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>1636</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02851-13</pub-id><pub-id pub-id-type="pmid">24257598</pub-id><pub-id pub-id-type="pmcid">PMC3911576</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rogers</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Lamens</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Tollefson</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>JV</given-names></name>. <article-title>Genetic absence of PD-L1 does not restore CD8+ T cell function during respiratory virus infection and delays virus clearance</article-title>. <source>J Virol</source>. <year>2024</year>;<volume>98</volume>(<issue>10</issue>):e0079724. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/jvi.00797-24</pub-id><pub-id pub-id-type="pmid">39311697</pub-id><pub-id pub-id-type="pmcid">PMC11495042</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma</article-title>. <source>Mol Ther Oncolytics</source>. <year>2022</year>;<volume>24</volume>:<fpage>522</fpage>&#8211;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.omto.2022.01.011</pub-id><pub-id pub-id-type="pmid">35229030</pub-id><pub-id pub-id-type="pmcid">PMC8851082</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>Z-L</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Z-J</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>T-Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X-Y</given-names></name>, <etal>et al</etal>. <article-title>Revealing the characteristics of ZIKV infection through tissue-specific transcriptome sequencing analysis</article-title>. <source>BMC Genomics</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>697</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12864-022-08919-5</pub-id><pub-id pub-id-type="pmid">36209057</pub-id><pub-id pub-id-type="pmcid">PMC9546753</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Blackmer</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Ard</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2421</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-020-16217-5</pub-id><pub-id pub-id-type="pmid">32415086</pub-id><pub-id pub-id-type="pmcid">PMC7229207</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dowall</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Rayner</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pearson</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Lineage-dependent differences in the disease progression of Zika virus infection in type-I interferon receptor knockout (A129) mice</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2017</year>;<volume>11</volume>(<issue>7</issue>):e0005704. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0005704</pub-id><pub-id pub-id-type="pmid">28672028</pub-id><pub-id pub-id-type="pmcid">PMC5510909</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fei</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages</article-title>. <source>Exp Ther Med</source>. <year>2021</year>;<volume>21</volume>(<issue>4</issue>):<fpage>400</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/etm.2021.9831</pub-id><pub-id pub-id-type="pmid">33680122</pub-id><pub-id pub-id-type="pmcid">PMC7918472</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vummidi</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Farrera-Soler</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Daguer</surname><given-names>J-P</given-names></name>, <name name-style="western"><surname>Dockerill</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barluenga</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Winssinger</surname><given-names>N</given-names></name>. <article-title>A mating mechanism to generate diversity for the Darwinian selection of DNA-encoded synthetic molecules</article-title>. <source>Nat Chem</source>. <year>2022</year>;<volume>14</volume>(<issue>2</issue>):<fpage>141</fpage>&#8211;<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41557-021-00829-5</pub-id><pub-id pub-id-type="pmid">34873299</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aktas</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kucuksezer</surname><given-names>UC</given-names></name>, <name name-style="western"><surname>Bilgic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Erten</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Deniz</surname><given-names>G</given-names></name>. <article-title>Relationship between CD107a expression and cytotoxic activity</article-title>. <source>Cell Immunol</source>. <year>2009</year>;<volume>254</volume>(<issue>2</issue>):<fpage>149</fpage>&#8211;<lpage>54</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cellimm.2008.08.007</pub-id><pub-id pub-id-type="pmid">18835598</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Garcia-Diaz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Saco</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Escuin-Ordinas</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>GA</given-names></name>, <etal>et al</etal>. <article-title>Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression</article-title>. <source>Cell Rep</source>. <year>2017</year>;<volume>19</volume>(<issue>6</issue>):<fpage>1189</fpage>&#8211;<lpage>201</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.031</pub-id><pub-id pub-id-type="pmid">28494868</pub-id><pub-id pub-id-type="pmcid">PMC6420824</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Muthuraj</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Sahoo</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Kraus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bruett</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Annamalai</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Pattnaik</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Zika virus infection induces endoplasmic reticulum stress and apoptosis in placental trophoblasts</article-title>. <source>Cell Death Discov</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>24</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41420-020-00379-8</pub-id><pub-id pub-id-type="pmid">33500388</pub-id><pub-id pub-id-type="pmcid">PMC7838309</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gladwyn-Ng</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cord&#243;n-Barris</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Alfano</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Creppe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Couderc</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Morelli</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Stress-induced unfolded protein response contributes to Zika virus-associated microcephaly</article-title>. <source>Nat Neurosci</source>. <year>2018</year>;<volume>21</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41593-017-0038-4</pub-id><pub-id pub-id-type="pmid">29230053</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chou</surname><given-names>C-W</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>R-Y</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>L-C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C-F</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H-H</given-names></name>, <etal>et al</etal>. <article-title>The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer</article-title>. <source>Am J Cancer Res</source>. <year>2020</year>;<volume>10</volume>(<issue>8</issue>):<fpage>2621</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="pmid">32905506</pub-id><pub-id pub-id-type="pmcid">PMC7471351</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ji</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody</article-title>. <source>EMBO Mol Med</source>. <year>2024</year>;<volume>16</volume>(<issue>3</issue>):<fpage>575</fpage>&#8211;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s44321-024-00026-0</pub-id><pub-id pub-id-type="pmid">38366162</pub-id><pub-id pub-id-type="pmcid">PMC10940662</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>H-C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S-H</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>G-C</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>W-C</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>C-C</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>C-P</given-names></name>, <etal>et al</etal>. <article-title>Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion</article-title>. <source>J Med Virol</source>. <year>2023</year>;<volume>95</volume>(<issue>2</issue>):e28478. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jmv.28478</pub-id><pub-id pub-id-type="pmid">36609964</pub-id><pub-id pub-id-type="pmcid">PMC10107526</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cha</surname><given-names>J-H</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>L-C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C-W</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Hung</surname><given-names>M-C</given-names></name>. <article-title>Mechanisms Controlling PD-L1 Expression in Cancer</article-title>. <source>Mol Cell</source>. <year>2019</year>;<volume>76</volume>(<issue>3</issue>):<fpage>359</fpage>&#8211;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.030</pub-id><pub-id pub-id-type="pmid">31668929</pub-id><pub-id pub-id-type="pmcid">PMC6981282</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mezzadra</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name>. <article-title>Regulation and function of the PD-L1 checkpoint</article-title>. <source>Immunity</source>. <year>2018</year>;<volume>48</volume>:<fpage>434</fpage>&#8211;<lpage>52</lpage>.&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.014</pub-id><pub-id pub-id-type="pmid">29562194</pub-id><pub-id pub-id-type="pmcid">PMC7116507</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Paschall</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Waller</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Sabbatini</surname><given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion</article-title>. <source>J Natl Cancer Inst</source>. <year>2017</year>;<volume>109</volume>(<issue>6</issue>):djw283. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jnci/djw283</pub-id><pub-id pub-id-type="pmid">28131992</pub-id><pub-id pub-id-type="pmcid">PMC5291187</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q-Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Characterization of dengue virus NS4A and NS4B protein interaction</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>(<issue>7</issue>):<fpage>3455</fpage>&#8211;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.03453-14</pub-id><pub-id pub-id-type="pmid">25568208</pub-id><pub-id pub-id-type="pmcid">PMC4403404</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munro</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pelham</surname><given-names>HR</given-names></name>. <article-title>An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein</article-title>. <source>Cell</source>. <year>1986</year>;<volume>46</volume>(<issue>2</issue>):<fpage>291</fpage>&#8211;<lpage>300</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0092-8674(86)90746-4</pub-id><pub-id pub-id-type="pmid">3087629</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>C-P</given-names></name>, <name name-style="western"><surname>Roy-Burman</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2008</year>;<volume>105</volume>(<issue>49</issue>):<fpage>19444</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.0807691105</pub-id><pub-id pub-id-type="pmid">19033462</pub-id><pub-id pub-id-type="pmcid">PMC2614780</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref057"><label>57</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Koumenis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Naczki</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Koritzinsky</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rastani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Diehl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha</article-title>. <source>Mol Cell Biol</source>. <year>2002</year>;<volume>22</volume>(<issue>21</issue>):<fpage>7405</fpage>&#8211;<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/MCB.22.21.7405-7416.2002</pub-id><pub-id pub-id-type="pmid">12370288</pub-id><pub-id pub-id-type="pmcid">PMC135664</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref058"><label>58</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sornjai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Promma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Priewkhiew</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ramphan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jaratsittisin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jinagool</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>The interaction of Grp78 and Zika virus E and NS1 proteins occurs in a chaperone-client manner</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>:<fpage>10407</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-61195-z</pub-id><pub-id pub-id-type="pmid">38710792</pub-id><pub-id pub-id-type="pmcid">PMC11074156</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref059"><label>59</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>P-Y</given-names></name>. <article-title>Flavivirus NS4B protein: Structure, function, and antiviral discovery</article-title>. <source>Antiviral Res</source>. <year>2022</year>;<volume>207</volume>:<fpage>105423</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.antiviral.2022.105423</pub-id><pub-id pub-id-type="pmid">36179934</pub-id><pub-id pub-id-type="pmcid">PMC10294551</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref060"><label>60</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shin</surname><given-names>W-J</given-names></name>, <name name-style="western"><surname>Ha</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Machida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>AS</given-names></name>. <article-title>The stress-inducible ER chaperone GRP78/BiP is upregulated during SARS-CoV-2 infection and acts as a pro-viral protein</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>6551</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-022-34065-3</pub-id><pub-id pub-id-type="pmid">36376289</pub-id><pub-id pub-id-type="pmcid">PMC9663498</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref061"><label>61</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Royle</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ram&#237;rez-Santana</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Akpunarlieva</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Donald</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Gestuveo</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Anaya</surname><given-names>J-M</given-names></name>, <etal>et al</etal>. <article-title>Glucose-Regulated Protein 78 Interacts with Zika Virus Envelope Protein and Contributes to a Productive Infection</article-title>. <source>Viruses</source>. <year>2020</year>;<volume>12</volume>(<issue>5</issue>):<fpage>524</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/v12050524</pub-id><pub-id pub-id-type="pmid">32397571</pub-id><pub-id pub-id-type="pmcid">PMC7290722</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref062"><label>62</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Placental alkaline phosphatase promotes Zika virus replication by stabilizing viral proteins through BIP</article-title>. <source>mBio</source>. <year>2020</year>;<volume>11</volume>:e01716-20. <pub-id pub-id-type="doi">10.1128/mBio.01716-20</pub-id><pub-id pub-id-type="pmid">32934082</pub-id><pub-id pub-id-type="pmcid">PMC7492734</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref063"><label>63</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khongwichit</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sornjai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jitobaom</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Greenwood</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Greenwood</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Hitakarun</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A functional interaction between GRP78 and Zika virus E protein</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>393</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-79803-z</pub-id><pub-id pub-id-type="pmid">33432092</pub-id><pub-id pub-id-type="pmcid">PMC7801745</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref064"><label>64</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Adam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Fontes-Garfias</surname><given-names>CR</given-names></name>, <etal>et al</etal>. <article-title>An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses</article-title>. <source>NPJ Vaccines</source>. <year>2019</year>;<volume>4</volume>:<fpage>48</fpage>.&#160;<pub-id pub-id-type="doi">10.1038/s41541-019-0143-3</pub-id><pub-id pub-id-type="pmid">31815005</pub-id><pub-id pub-id-type="pmcid">PMC6883050</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref065"><label>65</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kublin</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Whitney</surname><given-names>JB</given-names></name>. <article-title>Zika virus research models</article-title>. <source>Virus Res</source>. <year>2018</year>;<volume>254</volume>:<fpage>15</fpage>&#8211;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.virusres.2017.07.025</pub-id><pub-id pub-id-type="pmid">28811170</pub-id><pub-id pub-id-type="pmcid">PMC5809325</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref066"><label>66</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Balint</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Montemarano</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ashkar</surname><given-names>AA</given-names></name>. <article-title>From mosquito bites to sexual transmission: evaluating mouse models of Zika virus infection</article-title>. <source>Viruses</source>. <year>2021</year>;<volume>13</volume>:<fpage>2244</fpage>.&#160;<pub-id pub-id-type="doi">10.3390/v13112244</pub-id><pub-id pub-id-type="pmid">34835050</pub-id><pub-id pub-id-type="pmcid">PMC8625727</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref067"><label>67</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rossi</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Tesh</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Azar</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Muruato</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Hanley</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Auguste</surname><given-names>AJ</given-names></name>, <etal>et al</etal>. <article-title>Characterization of a novel murine model to study Zika virus</article-title>. <source>Am J Trop Med Hyg</source>. <year>2016</year>;<volume>94</volume>:<fpage>1362</fpage>&#8211;<lpage>9</lpage>.&#160;<pub-id pub-id-type="doi">10.4269/ajtmh.16-0111</pub-id>&#160; <pub-id pub-id-type="pmid">27022155</pub-id><pub-id pub-id-type="pmcid">PMC4889758</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref068"><label>68</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Aliota</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Caine</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Larkin</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Camacho</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Osorio</surname><given-names>JE</given-names></name>. <article-title>Characterization of Lethal Zika Virus Infection in AG129 Mice</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):e0004682. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0004682</pub-id><pub-id pub-id-type="pmid">27093158</pub-id><pub-id pub-id-type="pmcid">PMC4836712</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref069"><label>69</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Busselaar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sijbranda</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Borst</surname><given-names>J</given-names></name>. <article-title>The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer</article-title>. <source>Immunol Lett</source>. <year>2024</year>;<volume>270</volume>:<fpage>106938</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.imlet.2024.106938</pub-id><pub-id pub-id-type="pmid">39490629</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref070"><label>70</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bohm</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Vangorder-Braid</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Jaeger</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Moriarty</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Baczenas</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>NC</given-names></name>, <etal>et al</etal>. <article-title>Zika Virus Infection of Pregnant Ifnar1-/- Mice Triggers Strain-Specific Differences in Fetal Outcomes</article-title>. <source>J Virol</source>. <year>2021</year>;<volume>95</volume>(<issue>21</issue>):e0081821. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.00818-21</pub-id><pub-id pub-id-type="pmid">34379510</pub-id><pub-id pub-id-type="pmcid">PMC8513483</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref071"><label>71</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bohm</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Casta&#241;eda</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Cameron</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Aliota</surname><given-names>MT</given-names></name>. <article-title>Zika virus-induced fetal demise is triggered by strain- and dose-specific RLR-driven activation of the interferon response in the decidua, placenta, and fetus in Ifnar1-/- mice</article-title>. <source>J Virol</source>. <year>2025</year>;<volume>99</volume>(<issue>6</issue>):e0066625. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/jvi.00666-25</pub-id><pub-id pub-id-type="pmid">40401980</pub-id><pub-id pub-id-type="pmcid">PMC12172451</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref072"><label>72</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Regla-Nava</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Elong Ngono</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Viramontes</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Huynh</surname><given-names>A-T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y-T</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>A-VT</given-names></name>, <etal>et al</etal>. <article-title>Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>3042</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-018-05458-0</pub-id><pub-id pub-id-type="pmid">30072692</pub-id><pub-id pub-id-type="pmcid">PMC6072705</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref073"><label>73</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Andrade</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>E</given-names></name>. <article-title>Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure</article-title>. <source>Virus Research</source>. <year>2018</year>;<volume>254</volume>:<fpage>27</fpage>&#8211;<lpage>33</lpage>.&#160;<pub-id pub-id-type="doi">10.1016/j.virusres.2017.06.019</pub-id>&#160;<pub-id pub-id-type="pmid">28655548</pub-id><pub-id pub-id-type="pmcid">PMC5743770</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref074"><label>74</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>An</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Japanese Encephalitis Vaccine Generates Cross-Reactive Memory T Cell Responses to Zika Virus in Humans</article-title>. <source>J Trop Med</source>. <year>2022</year>;<volume>2022</volume>:<fpage>8379286</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2022/8379286</pub-id><pub-id pub-id-type="pmid">36444358</pub-id><pub-id pub-id-type="pmcid">PMC9701130</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref075"><label>75</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pan</surname><given-names>Y-G</given-names></name>, <name name-style="western"><surname>Aiamkitsumrit</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bartolo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lavery</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Marc</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Vaccination reshapes the virus-specific T cell repertoire in unexposed adults</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>(<issue>6</issue>):1245-1256.e5. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2021.04.023</pub-id><pub-id pub-id-type="pmid">34004140</pub-id><pub-id pub-id-type="pmcid">PMC8192456</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref076"><label>76</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kalimuddin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tham</surname><given-names>CYL</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>YFZ</given-names></name>, <name name-style="western"><surname>Hang</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Kunasegaran</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chia</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans</article-title>. <source>Nat Microbiol</source>. <year>2025</year>;<volume>10</volume>(<issue>2</issue>):<fpage>374</fpage>&#8211;<lpage>87</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-024-01903-7</pub-id><pub-id pub-id-type="pmid">39794472</pub-id><pub-id pub-id-type="pmcid">PMC11790491</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref077"><label>77</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Characterization of CD8+ T cells in immune-privileged organs of ZIKV-infected Ifnar1-/- mice</article-title>. <source>J Virol</source>. <year>2024</year>;<volume>98</volume>(<issue>1</issue>):e0078923. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/jvi.00789-23</pub-id><pub-id pub-id-type="pmid">38168677</pub-id><pub-id pub-id-type="pmcid">PMC10805016</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref078"><label>78</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>C-M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells</article-title>. <source>J Biol Chem</source>. <year>2018</year>;<volume>293</volume>(<issue>30</issue>):<fpage>11709</fpage>&#8211;<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1074/jbc.RA118.001897</pub-id><pub-id pub-id-type="pmid">29887526</pub-id><pub-id pub-id-type="pmcid">PMC6066311</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref079"><label>79</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>P-H</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>Z-W</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>J-J</given-names></name>, <name name-style="western"><surname>Siu</surname><given-names>K-L</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>W-W</given-names></name>, <name name-style="western"><surname>Chaudhary</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16</article-title>. <source>EMBO Rep</source>. <year>2018</year>;<volume>19</volume>(<issue>10</issue>):e45737. <comment>doi: </comment><pub-id pub-id-type="doi">10.15252/embr.201845737</pub-id><pub-id pub-id-type="pmid">30104205</pub-id><pub-id pub-id-type="pmcid">PMC6172465</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref080"><label>80</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Qu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Enhanced stability of M1 protein mediated by a phospho-resistant mutation promotes the replication of prevailing avian influenza virus in mammals</article-title>. <source>PLoS Pathog</source>. <year>2022</year>;<volume>18</volume>(<issue>7</issue>):e1010645. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1010645</pub-id><pub-id pub-id-type="pmid">35793327</pub-id><pub-id pub-id-type="pmcid">PMC9258882</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref081"><label>81</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ye</surname><given-names>Z-W</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals</article-title>. <source>Cell Mol Immunol</source>. <year>2022</year>;<volume>19</volume>(<issue>5</issue>):<fpage>588</fpage>&#8211;<lpage>601</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41423-022-00855-4</pub-id><pub-id pub-id-type="pmid">35352010</pub-id><pub-id pub-id-type="pmcid">PMC8961489</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref082"><label>82</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chan</surname><given-names>JF-W</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chik</surname><given-names>KK-H</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>CC-S</given-names></name>, <etal>et al</etal>. <article-title>The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</article-title>. <source>Antiviral Res</source>. <year>2018</year>;<volume>160</volume>:<fpage>38</fpage>&#8211;<lpage>47</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.007</pub-id><pub-id pub-id-type="pmid">30326204</pub-id><pub-id pub-id-type="pmcid">PMC7113887</pub-id></mixed-citation></ref><ref id="ppat.1013457.ref083"><label>83</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sotcheff</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JY-C</given-names></name>, <name name-style="western"><surname>Elrod</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jaworski</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kuyumcu-Martinez</surname><given-names>MN</given-names></name>, <etal>et al</etal>. <article-title>Zika Virus Infection Alters Gene Expression and Poly-Adenylation Patterns in Placental Cells</article-title>. <source>Pathogens</source>. <year>2022</year>;<volume>11</volume>(<issue>8</issue>):<fpage>936</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/pathogens11080936</pub-id><pub-id pub-id-type="pmid">36015056</pub-id><pub-id pub-id-type="pmcid">PMC9414685</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>